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Dialkynylimidazoles as Irreversible MAPK Inhibitors, Kinase Docking 
Site Probes, and Anti-cancer Agents  
 
Jing Li, Ph.D. 
The University of Texas at Austin, 2011 
 
Supervisor: Sean Michael Kerwin 
 
This dissertation research was aimed at investigating an interesting class of 1,2-
dialkynylimidazoles as: 1. irreversible p38 MAP kinase -isoform (p38) inhibitors; 2. 
p38 docking site probes; 3. anti-cancer agents.  
Based on the mild, thermal rearrangement of 1,2-dialkynylimidazoles to reactive 
carbene or diradical intermediates, a series of 1,2-dialkynylimidazoles was designed as 
potential irreversible p38inhibitors. The synthesis of these dialkynylimidazoles and 
their kinase inhibition activity were reported. Interestingly, one of the 1-ethynyl-
substituted dialkynylimidazoles is a potent (IC50 = 200 nM) and selective inhibitor of 
p38α. Additionally, this compound covalently modifies p38α as determined by ESI-MS 
after 12 h incubation at 37 °C. The unique kinase inhibition, covalent kinase adduct 
formation, and minimal CYP450 2D6 inhibition by this compound demonstrate that 
dialkynylimidazoles are a new, promising class of p38α inhibitors. 
Blocking docking interactions between kinase network partners is a promising 
alternative approach for selectively inhibiting kinases. The second project involves the 
identification of a new class of small molecules, covalent p38α MAP kinase docking site 
probes. We proposed that the mechanism may involve the addition of a thiol to the N-
ethynyl group. Moreover, we demonstrated that such probes can be used fluorescently to 
 viii 
label p38α both in vitro and in cells via azide-alkyne “Click” chemistry.  This serves as 
the basis of an assay that can be used to identify inhibitors that specifically target the 
substrate docking site of p38α.  
The last project was focused on evaluating a new class of 1,2-dialkynylimidazoles 
as anti-cancer agents. One 1,2-dialkynylimidazole analog was found to be cytotoxic 
against a range of human cancer lines and to induce apoptosis in the human non-small 
cell lung cancer cell line A549. In order to elucidate the relationship between the 
structural basis and role of the thermal generation of diradical or carbene intermediates, a 
series of dialkynylimidazoles and related N-alkynylimidazoles was prepared and their 
cytotoxicity was determined against A549 cell line. Although the experimentally 
determined activation energy is in excellent agreement with that predicated from the DFT 
calculation, there is no correlation between the rate of Bergman cyclization and 
cytotoxicity to A549 cells. An alternative mechanism was proposed involving the 
unexpected selective thiol addition to the N-ethynyl group of certain 1,2-
dialkynylimidazoles. 
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  Chapter 1:  Introduction 
 
1.1. PROTEIN KINASES AS DRUG TARGETS   
Protein kinases are key regulators in signal transduction pathways. The human genome 
encodes approximately 518 protein kinases, which share a conserved catalytic domain but which 
are different in how catalysis is regulated (1). Deregulation of kinase activity has been implicated 
in a number of diseases, ranging from cancer and inflammation to diabetes, and neurological and 
metabolic disorders. Thus, protein kinases are considered as a promising drug class for the 
treatment of these diseases (1, 2). To date, nearly 30 distinct kinase targets have been developed 
to the level of Phase I clinical trial, and 11 kinase inhibitors have been approved by the US Food 
and Drug Administration for cancer treatment (3).   
The pharmaceutical industry became interested in protein kinases after the discovery of 
staurosporine, which is an antifungal agent produced by bacteria of the genus Streptomyces. 
Staurosporine was found to be a nanomolar inhibitor of protein kinase C (Figure 1.1) (4). 
Subsequently, several companies began making derivatives of this bisindolyl maleimide. 
However, these derivatives later were shown to lack specificity, inhibiting several other protein 
kinases (5, 6).  
A landmark event occurred in May 2001 when Imatinib (Gleevec
TM
) was approved for 
clinical use. Gleevec was the first approved small molecule drug for cancer therapy, targeting the 
Abelson tyrosine kinase (ABL) (Figure 1.1). ABL becomes fused to the oncogenic breakpoint 
cluster region (BCR) protein as a result of chromosome rearrangement in nearly all types of 
chronic myeloid leukeamia (CML). The success of Gleevec has generated a great amount of 
interest in identifying aberrantly regulated signaling pathways and developing novel small 





































1.2. MITOGEN ACTIVATED PROTEIN KINASE SIGNALING 
Mitogen-activated protein kinases (MAPK) are important components of signaling 
cascades, which convert extracellular stimuli into intracellular responses. All eukaryotic cells 
possess multiple MAPK pathways that regulate diverse cellular activities, such as motility, 
survival, apoptosis and differentiation. So far, seven groups of MAPKs have been characterized 
in mammals. Conventional MAPKs are composed of extracellular signal-regulated kinases 1/2 
(ERK1/2), c-Jun amino-terminal kinases 1/2/3 (JNK1/2/3), p38 isoforms (,,,and, and 
ERK5. Atypical MAPKs comprise ERK 3/4, ERK7, and Nemo-like kinase (NLK) (9-11). 
MAPKs can be activated by a variety of stimuli: ERK1/2 are activated by growth factors 
including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), nerve growth 
factor (NGF) (12), insulin (13), and to a lesser extent by ligands for heterotrimeric G protein-
coupled receptors (GPCR), cytokines, osmotic stress and microtubule disorganization (14). JNKs 
and p38 MAPKs are activated in response to stress stimuli including osmotic shock, ionizing 
radiation, ischemia and cytokine stimulation (15). Each conventional MAPK cascade is 
composed of three evolutionarily conserved kinases: a MAPKK kinase (MAPKKK), MAPK 
kinase (MAPKK), and a MAPK. Similar to many other protein kinases, the 
activation/phosphorylation of MAPKs occurs on a flexible loop, termed the phosphorylation loop 
or activation loop. Upon activation, MAPKs adopt conformational changes that relieve steric 
blocking and stabilize the activation loop in order to facilitate substrate binding and enhance the 
catalytic activity of MAPKs (16). In response to extracellular stimuli, MAPKKKs are activated 
through phosphorylation as a result of their interaction with a small GTP-binding protein of the 
Ras/Rho family (17, 18). MAPKKK phosphorylation leads to activation of a MAPKK, which, in 
turn, stimulates MAPK activity through dual phosphorylation on Thr and Tyr residues (Thr-X-
Tyr). Subsequently, MAPKs phosphorylate their downstream substrates, such as phospholipases, 
transcription factors and cytoskeletal proteins, as well as several protein kinases, termed MAPK-
activated protein kinases (MKs) (19). 
4 
The activation mechanism of atypical MAPKs still remains elusive. These kinases are not 
organized into a conventional set of three-tiered kinase cascades. The Thr-X-Tyr motif is absent 
in ERK3/4 and NLK; instead, a Gly or Glu residue replaces the Tyr. ERK7 appears to 
autophosphorylate on the Thr-Glu-Tyr motif. However, once activated, both conventional and 
atypical kinases are Pro-directed kinases, namely phosphorylating substrates on Ser or Thr 




















1.3. P38 MAPK 
p38 MAPK belongs to the class of serine-threonine MAP kinases. To date, four isoforms 
have been identified ,,,and), and they have been shown to be highly homologous and 
widely expressed in various tissues (21). p38MAPK was first identified as a protein that was 
rapidly phosphorylated on Tyr residue in response to lipopolysaccharide (LPS) stimulation (22), 
and p38 was a target of pyridinylimidazole drugs that inhibited the production of pro-
inflammatory cytokines (23). Of the four isoforms, p38 is ubiquitously expressed and has been 
extensively studied. The other isoforms seem to be expressed in a more tissue specific manner; 
for example, p38is predominately expressed in the brain, p38 in skeletal muscle, and p38 in 
endocrine glands (24).  
In response to a variety of physical and chemical stresses, for instance, oxidative stress, 
UV irradiation, hypoxia, ischemia, and cytokines including interleukin-1 (IL-1) and tumor 
necrosis factor alpha (TNF), p38 kinases are phosphorylated on a conserved Thr-Gly-Tyr 
(TGY) motif by three dual-specificity MAPKKs (MKKs). MKK3 and MKK6 are highly specific 
for p38, as they do not activate ERK1/2 or JNK. MKK6 can phosphorylate all four p38 MAPK 
isoforms, however, MKK3 preferentially phosphorylates ,,and (25, 26). Two mechanisms 
may account for the specificity in p38 activation: 1. the selective formation of functional 
complexes between MKK3/6 and different p38 isoforms; 2. the selective recognition of the 
activation loop of p38 isoforms by MKK3/6 (27). Additionally, p38 can be phosphorylated by 
MKK4, an activator of the JNK cascade (28, 29).  
Besides the canonical p38 MAPK-activation pathway described above, p38 (and 
probably p38) can be activated by several non-canonical mechanisms. An alternative activation 
mechanism involves phosphorylation of p38 on Tyr323 by the T-cell receptor-proximal 
tyrosine kinases and p56
lck
, leading to p38 autophosphorylation on the activation loop and 
consequently increasing p38 kinase activity towards substrates (30). The second reported 
alternative pathway of p38activation involves TAK1-binding protein 1 (TAB1), which binds 
selectively to the p38isoform and induces p38 autophosphorylation (31, 32). The last non-
6 
canonical p38 MAPK-activation pathway has been proposed to operate upon down-regulation of 
the protein phosphatase Cdc7. This pathway induces an abortive S-phase leading to p38–
mediated apoptosis in HeLa cells (33). 
p38 MAPKs have been detected in both the nucleus and cytoplasm of quiescent cells. 
However, upon cell stimulation, the cellular localization of p38 is controversial. Some evidence 
indicates that p38 translocates to the nucleus from the cytoplasm (34), whereas other evidence 
shows that activated p38 is present in the cytosol (35). The difference in pools of p38 may 
explain the discrepancy, as p38 may be located in different subcellular compartments and bound 
to different partners (16).   
The p38 MAPK signaling cascade plays an important role in normal immune and 
inflammatory responses. p38 MAPK activation lead to increased pro-inflammatory cytokine 
production by modulating transcription factors, such as NF-B (16, 36), or at the mRNA level, 
by modulating cytokine mRNA stability and translation through regulating MNK1(37) and 
MK2/3 (38). Furthermore, p38 MAPKs also play roles in cell proliferation and survival. Some 
studies show that p38 has a pro-survival function, and others report that p38 activity is 










1.4. P38 MAPK INHIBITORS 
Since the initial discovery of p38 MAPK in the early 1990s, there has been a great 
interest in identifying small molecules that target this kinase for the treatment of various 
inflammatory diseases (39). More than 234 patents regarding p38 MAPK inhibitors have been 
published since 1996, and approximately 20 inhibitors have entered clinical trials (40). However, 
the development of many p38 MAPK inhibitors has been hindered due to poor toxicity profiles 
such as liver toxicity, cardiotoxicity, lightheadedness, CNS toxicity, skin irritation and infection 
(41). The vast majority of p38 MAPK inhibitors has targeted the highly conserved ATP binding 
pocket. A small number of inhibitors have been shown to interact with other binding sites.  
1.4.1. ATP-competitive and DFG-out allosteric p38MAPK inhibitors 
 Following the discovery of the pyridinylimidazole class of p38 MAPK inhibitors, 
exemplified by SB-203580, multiple pharmaceutical companies, e.g. Merck, Roche, Vertex, 
Aventis and Amgen, explored substituent modification as well as imidazole and/or pyridine ring 
replacement (42, 43). These efforts resulted in a number of p38 inhibitors that either 
maintained or improved potency (Figure 1.2). Many of these inhibitors have a similar binding 
mode to the p38 active site as the original SB-203580 inhibitor (Figure 1.3). Two key 
interactions between p38 and inhibitors have been observed from X-ray co-crystal structures, 
including a hydrogen bond interaction with the hinge region Met109-NH and a lipophilic 
interaction of the inhibitor with hydrophobic pocket I that is not accessed by ATP.  A non-
conserved residue, the so-called gatekeeper, controls the access to hydrophobic pocket I.  This 
residue is relatively small in p38 (Thr106) whereas 75 % of all kinases have bulky residues in 
this position. Thus, kinases with large gatekeeper residues are usually insensitive to 
pyridinylimidazoles and related p38 inhibitors. Most of these inhibitors are highly potent in vitro 
with IC50 values in the low nanomolar and sub-nanomolar range. However, the drawback of this 
class is that these compounds also interact with cytochrome P450 enzymes which are associated 
with liver toxicity (42). Many efforts have been made to reduce cytochrome interaction, 
8 
however, inhibitors with reduced cytochrome inhibition are also less potent kinase inhibitors 
























SB 203580 SB 681323 AMG 548 TAK 715
NH2
 
Figure 1.2. Pyridinylimidazole and pyridinylimidazole-like p38 MAPK inhibitors. 
 
Figure 1.3. Crystal structure of p38in complex with SB 220025 (1BL7). 
 The N,N’-diaryl urea class of inhibitors was independently discovered at Bayer, 
Boehringer Ingelheim and Vertex (45-47). The most representative example is BIRB 796. BIRB 
796 binds to a novel allosteric site, which is spatially distinct from the ATP binding site, causing 
a large conformational change. This compound has a reported Kd of 0.05 nM for inactive p38 
and inhibits the phosphorylation of p38 in the picomolar range (Figure 1.4). According to the 
crystal structure of BIRB 796 with human p38, the tert-butyl group is placed in the DFG pocket 
9 
and the naphthalenyl group is positioned in hydrophobic pocket I. Three hydrogen bonds are 
formed, between one urea NH and Glu71, carbonyl-O and the amide NH of Asp168, and 
morpholine-O and the linker residue Met109 (Figure 1.5). This compound advanced to phase 
II/III clinical trials for the treatment of autoimmune disorders. Unfortunately, due to non-












BIRB 796  
Figure 1.4. DFG-out p38 MAPK inhibitor.  
 
Figure 1.5. Crystal structure of p38in complex with BIRB 796 (1KV2). 
 Bicyclic 6,6-heterocycles and related structures are an alternative structural class of p38 
inhibitors. The first compound from this class was developed by Vertex and has a high 
selectively profile (48, 49)
 
(Figure 1.6). To date, no crystal structure of this compound in 
10 
complex with p38 is available. Co-crystal structures of other analogs developed by Merck have 
been solved. So it has been proposed that the pyrimidopyridazinone ring of Vertx compound 
may also bind to p38 by forming two hydrogen bonds to Met109-NH and Gly110-NH (Figure 
1.7). The peptide flip in the hinge region of p38 may account for the high selectivity of this 
compound. Vertex compound progressed to phase IIb clinical trials. However, development was 









VX 745  
Figure 1.6. p38 MAP kinase inhibitor VX 745. 
 
 
Figure 1.7. Crystal structure of p38in complex with quinazolinone (1OVE). 
11 
 The last structural class is linear binders: diarylketones and indole amides (Figure 1.8). 
Ketopyrzole was identified in a high throughput screening assay from Roche (48). Based on the 
crystal structure, the carbonyl-O forms a hydrogen bond to Met109, and the pyrzole rings forms 
two hydrogen bonds to His107-O and Thr106. The 4-fluorophenyl ring is placed in hydrophobic 
pocket I (Figure 1.9) (42). This compound shows high selectivity and efficacy. It was selected as 











Figure 1.8. Linear binder RO 3201195. 
 
          
Figure 1.9. Crystal structure of p38in complex with RO 3201195 (2GFS). 
1.4.2. Non-ATP competitive p38 MAPK inhibitors 
 In 2004, a substrate selective and non-ATP competitive MAPK p38 inhibitor was 
discovered (Figure 1.10). This small molecule inhibited the phosphorylation of MK2a with a Ki 
12 
of 330 nM, and inhibited the phosphorylation of ATF2 with a Ki of more than 20 M. Isothermal 
titration calorimetry analysis indicated the inhibitor did not compete with ATP for p38, and 
surface plasmon resonance study showed that this inhibitor was not able to interrupt the binding 
of p38 to MK2a. Furthermore, a deuterium exchange mass spectrometry (DXMS) study 
suggested that this compound binds in the vicinity of the p38 MAPK active site, resulting in 
perturbations to ATP binding site and docking groove residues (49).  
 Recently, Comess et al. reported the identification and characterization of several non-
ATP competitive p38 MAPK inhibitors through an affinity-based lead discovery campaign 
(Figure 1.10). The co-crystal structures showed that the inhibitor binds to a novel allosteric 
binding site located at the C-terminal lobe of p38 MAPK. This inhibitor directly inhibits p38 















p38 Allosteric Inhibitor 







1.5. COVALENT KINASE INHIBITORS 
The majority of known kinase inhibitors are ATP-competitive. The main challenge in 
kinase inhibitor discovery has been poor selectivity and the high intracellular concentration of 
the endogenous competitive substrate, ATP. An alternative strategy is to develop highly targeted 
covalent, irreversible inhibitors to overcome these challenges. Over the last decade, many efforts 
have been made towards covalent kinase inhibitors. Covalent inhibitors have shown exceptional 
potency in overcoming cellular ATP competition and selectivity that is currently faced by 
reversible kinase inhibitors (51).  
For example, the most well-characterized, selective irreversible inhibitors of epidermal 
growth factor receptor (EGFR), such as HKI-272 (52) and CL-387785 (53) and PD 168393 (54) 
were developed to target a relatively rare cysteine residue located at the lip of the ATP binding 
site (Figure 1.11). These molecules were rationally designed by appending an electrophile to the 
EGFR-selective 4-anilinoquinazoline and 4-anilinoquinoline-3-carbonitrile scaffolds, which 
undergo Michael addition reaction with the thiol present in the cysteine residue (Cys773). As a 
result, these inhibitors irreversibly block the binding of ATP to the kinase, rendering the kinase 
inactive. These compounds also show low reactivity with DTT in enzyme assays and glutathione 
in cellular assays, suggesting that their reactivity towards non-specific thiols are low (51). So far, 
five such EGFR kinase inhibitors are being investigated in lung cancer clinical trials (55-57). 
Additionally, irreversible inhibitors have also been shown to target several other kinases such as 
vascular endothelial growth factor receptor 2 (VEGFR2) (58), the Tec family kinase BTK (59) 



















































1.6. DOCKING INTERACTIONS IN MAPK CASCADE 
MAPKs recognize their substrates and regulators through docking interaction, and the 
docking interactions may account for the MAPK pathway efficiency and specificity (61, 62). At 
least two types of docking interactions between MAPKs and their substrates, activators and 
phosphatases have been identified. In both docking interactions, short motifs are found within 
substrates with a complementary pocket or groove on the kinase (11).  
The first docking motif is called the D domain (D site, domain, DEJL domain), which 
consists of a cluster of basic residues, a short spacer and a hydrophobic patch (Lys/Arg-Lys/Arg-
Xaa2-6--X-, where  is a hydrophobic residue, such as Leu, Iso, or Val) (63). The interactions 
between MAPK and D domains have been characterized by mutagenesis, hydrogen exchange-
mass spectrometry, and X-ray crystallography. The D domain motif was first identified in c-Jun 
involved in MAPK docking (64, 65).  Subsequently, sequences related to the D domain were also 
found in other transcription factors, including the MAPK-regulated bZIP, ETS, and MAD, and 
many MAPK regulatory proteins, including upstream activating kinases (MAPKKs), 
phosphatases (PTP-SL, STEP, and MKPs), and scaffold proteins (KSR) across different species 
(27, 64). The D-recruitment site (DRS) on MAP kinase is composed of acidic patch in the C-
terminal known as the CD (Common Docking) domain (66) and hydrophobic docking 
groove(67, 68) (or referred to as “ED) (63). 
The second MAPK docking domain is known as the DEF domain (Docking site for ERK, 
FXFP, F site or DEF site). The DEF domain consists of the Phe-Xaa-Phe-Pro sequence, where 
Xaa is any amino acid and one of the Phe residues can also be a Tyr (69-71). The DEF domain 
has been identified in a number of ERK1/2 substrates, located between 6 and 20 amino acids C 
terminal to the phosphoacceptor site. DEF domains are required for efficiently binding to 
ERK1/2 and subsequent phosphorylation (72, 73). Additionally, the DEF domain in the 
transcription factor SAP-1 has been reported to contribute to efficient phosphorylation by 
p38(74).
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Chang and Goldsmith reported crystallographic studies of p38 in complex with docking 
site peptides derived from substrate MEF2A and activating enzyme MKK3b. Both peptides bind 
to the site in the C-terminal domain of the kinase. Binding to this site induces conformational 
changes in the active site as well as structural disorder in the phosphorylation loop (68). 
Additionally, Bardwell demonstrated that all MAPKK D domain binding site bind better to their 
cognate MAPKs compared to non-cognate MAPKs. For instance, the MKK3 D domain peptide 
inhibits p38 with an IC50 of <10 nM, and this peptide does not inhibit JNK1 or JNK2 (75).  
 The hydrophobic docking groove in the DRS appears to be a great potential drug site 
target as it has a significant hydrophobic site (76, 77). The hydrophobic docking grooves vary 
significantly among p38, ERK2 and JNK’s. Interestingly, cysteine residues are present in the 
hydrophobic docking groove. P38 has two cysteine residues, Cys119 and C162, facing the 
pocket. ERK2 and JNK have one cysteine, Cys159 and Cys163, respectively. It has been 
suggested that covalent inhibitors could be developed directed towards cysteine (77).  
17 
1.7. ENEDIYNE AND BERGMAN CYCLIZATION 
The enediyne structural moiety, containing two acetylenic groups conjugated to a double 
bond [(Z)-3-ene-1,5-diyne], has been identified in several naturally occurring anticancer 
antibiotics (78, 79). The naturally occurring enediynes can be grouped into two classes based on 
the ring size of the enediyne core structure: the 9-membered ring enediyne and the 10-membered 
ring enediyne. Almost all the 9-membered ring enediynes with the exception of N199A2 are 
produced as chromophore-protein complexes, exemplified by neocarzinostatin (NCS), C-1027, 
kedarcidin and maduropeptin. In contrast, 10-membered ring enediynes are produced as isolated 
chromophores, exemplified by calicheamicin 

 (80), esperamicin A1 (81), dynemicin A (82), 
uncialamycin (83), namenamicin (84), and shishijimicin (Figure 1.13) (85). Some of these 
naturally occurring enediynes are able to kill cancer cells in vitro at concentrations as low as 10
-
12
M (86), and that has aroused interest in studying the mechanism of action of these agents, and 
which came from the studies by Bergman.  
In 1972, Robert Bergman and coworkers reported the Bergman cyclization involving the 
thermal rearranging of enediynes to reactive p-benzyne diradicals which then abstracts two 
hydrogens from solvent to form benzene (Figure 1.12) (87). It has been proposed that the 
generation of benzenoid diradicals from naturally occurring enediynes abstract hydrogen atoms 














































































































In the case of calicheamicin, it is stable to diradical-generating Bergman cyclization until 
activated via nucleophilic attack. Activation involves an intramolecular Michael addition to the 
cyclohexenone core followed by a bioreduction of the trisulfide to a thiolate anion. The resulting 




 triggers the Bergman cyclization, 























































In the case of dynemicin A, the triggering mechanism involves the reduction of 
anthraquinone to hydroquinone and the following rearrangement to open the epoxide. The ring 













































Activation of neocarzinostatin involves with nucloeophilic attack by a thiol group, such 
as glutathione, followed by epoxide ring opening to generate an eneyne cumulene, which then 


















































1.8. AZA-ENEDIYNE AND AZA-BERGMAN CYCLIZATION 
In 2007, David and Kerwin reported the first synthesis of a new class of enediynes, 3-
aza-enediynes (C,N-dialkynyl imines), and their thermal facile rearrangement to -
alkynylacrylonitriles, structurally related to the Bergman rearrangement of (Z)-hexenediynes 
(Figure 1.17) (95). The replacement of a sp
2
 carbon with a sp
2
 nitrogen may accelerate the 
Bergman cyclization by disturbing -delocalization and decreasing the degree of repulsion of the 
in-plane -orbitals in the transition state. The diradical intermediate, 2,5-didehydropyridine 
could not be trapped. Instead, (Z)--alkynylacrylonitrile, derived from the retro-aza-Bergman 
rearrangement, was exclusively isolated (95). Chen and co-workers reported the detection of a 
small amount of pyridine products by GC/MS in the thermolysis of the aza-enediyne under 
acidic conditions (96).  The overall conversion of 1 to 3 is highly exothermic. Computational 
studies suggested that the barrier for the aza-Bergman cyclization is lower than the barrier for the 
Bergman cyclization (96), and the barrier for the retro-aza-Bergman cyclization is also low with 








1 2 3  
Figure 1.17. aza-Bergman cyclization. 
Subsequently, Feng and co-workers in the Kerwin goup continued to study a series of 6-
unsubstituted and 6-triisopropylsilyl substituted 1-phenyl-4-aryl-3-aza-hexe-3-ene-1,4-diynes. 
Both enediynes undergo retro-aza-Bergman rearrangement to generate -alkynylacrylonitriles 
products (98). These and related aza-enediynes have been explored as potential DNA-cleaving 
anticancer agents with improved selectivity compared to the enediynes (95, 96, 98, 99). 
Numerous computational studies have been carried out so that aza-enediynes can be designed to 
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undergo a pH-dependent switch in reactivity mediated by changes in the kinetic stability and 
reactivity of the diradical upon nitrogen atom protonation (97, 100, 101).  
Additionally, Nadipuram and co-workers in the Kerwin group reported the synthesis of 
1,2-dialkynylimidazles, as a class of aza-enediynes, as well as their thermal cyclization and 
rearrangements (DAIms) (Scheme 1.18). Mild thermolysis of DAIms in the presence of 
chlorinated solvents or HCl leads to the isolation of imidazo[1,2-ɑ]pyridine (ImPy) products, 
which may result from the trapping of an initially-formed diradical intermediate via aza-
Bergman cyclization (102, 103). Thermolysis under neutral conditions in non-halogenated 
solvents affords products derived from trapping cyclopentapyrazine (CyPP) carbene 
intermediates by H-atom abstraction, C–H bond insertion, and alkene addition reactions (104-
106). The CyPP carbene is proposed to be derived from an intermediate cyclic cumulene that 
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Chapter 2  
Synthesis and biological evaluation of p38α kinase-targeting 
dialkynylimidazoles 
 
2.1. INTRODUCTION  
A number of p38α inhibitors have been synthesized and characterized (1). Although these 
compounds show good inhibition of p38α, many also inhibit other protein kinases with similar or 
greater potency (2). There has been a growing interest in irreversible inhibitors of protein kinases 
(3, 4), and a number of these drugs are in clinical trials (5). Advantages of irreversible kinase 
inhibition include increased selectivity (6), duration (7-9), and therapeutic utility, especially 
against kinases that are resistant to competitive, ATP-binding pocket-targeting drugs (10). 
Additionally, irreversible inhibitors and related selective, covalent kinase modifying small 
molecules are of interest as probes for chemical genetics studies (11). While certain natural 
products and ATP analogs irreversibly inhibit kinases (12, 13), none are selective towards p38α. 
Thus, there is a need to develop selective and irreversible inhibitors that target p38α. 
 
2.2. DESIGN AND SYNTHESIS OF P38 KINASE-TARGETING 1,2-DIALKYNYLIMIDAZOLES 
The novel thermal cyclization and rearrangement of 1,2-dialkynylimidazoles (DAIms) 
have been reported as described in Chapter 1. Non-covalent association between DAIms and a 
kinase may facilitate the rate-determining aza-Bergman cyclization. The formation of reactive 
diradical and carbene intermediates under mild conditions from DAIms has led us to propose that 
DAIms can be designed to undergo kinase binding-induced cyclization and covalent inactivation 
of specific kinase targets. Specifically, the structural similarity between DAIms and the known 
p38α inhibitors such as SB-203580 (14) and RWJ-67657 (15) (Figure 2.1) has inspired the 

















Figure 2.1. Examples of 4,5-diarylimidazole p38 inhibitors. 
An initial route to kinase-targeting dialkynylimidazoles is shown in Scheme 2.1 The 
known 4 (5)-(4-fluorophenyl)-5(4)-(4-pyridyl)imidazole 1 (16) was protected with trityl group. 
Interestingly, this reaction only afforded one regioisomer, which was assigned as the 5-(4-
fluorophenyl)-4-(4-pyridyl)imidazole 2 based on COSY and NOESY NMR. Compound 2 was 
deprotonated with n-BuLi at 0 °C, and quenched with I2 to give the 2-iodo-imidazole 3, which 
was deprotected in aqueous TFA to afford 4. Coupling of the lithium anion of imidazole 4, 
formed by deprotonation with LHMDS, with phenyl(phenylethynyl)-iodonium tosylate (17) 
afforded a 15 % yield of a 1:1 mixture of the regioisomeric N-alkynyl-2-iodoimidazoles 5 and 6. 
The separated regioisomers were subjected to Sonogashra coupling with various terminal 
acetylene partners to provide the regioisomeric dialkynylimidazoles 7 and 8. The regiochemical 
assignments within this series were made based on the X-ray crystal structure of 7b shown in 





































7a:  R = H (9 %)
7b:  R = CH2OH  (77 %) 
7c:  R = CH2CH2OH (40 %)
8a: R = H  (16 %)  
8b: R = CH2OH (48 %)






















    
Scheme 2.1. Synthesis of dialkynylimidazoles. Reagents and conditions: (a) Et3N, Ph3CCl, 











Figure 2.2. X-ray crystal structure of dialkynylimidazole 7b.                 
Although providing access to select kinase-targeting dialkynylimidazoles, the synthetic route 
shown in Scheme 2.1 suffers from a number of limitations associated with the alkynyliodonium 
coupling reaction. Only the phenylethynyl and TMS-ethynyl iodonium reagents could be 
employed in this coupling (18), and even in these cases, the yields are poor and mixtures of 
regioisomers are produced. We recently reported a copper-catalyzed N-alkynylation of imidazole 
with bromoalkyne (Scheme 2.2). An improved synthetic route to these dialkynylimidazoles 
employing this coupling reaction was devised (Scheme 2.3). Treating 4-fluorophenylimidazole 9 
(19) with TIPS-protected bromo-acetylene in the presence of catalytic CuI and 2-acetyl-
cyclohexanone as ligand affords a 9:1 mixture of regioisomeric alkynylimidazoles 10b and 10a, 
respectively, in 79 % yield (18). Iodination of the 2-position of 10b affords the 2-iodoimidazole 
11, which undergoes Sonogashira coupling with O-TIPS protected homopropargyl alcohol to 
give the dialkynylimidazole 12 in 73 % yield (20). Deprotonation of 12 with n-BuLi followed by 
36 
iodine quench affords the 5-iodoimidazole 13 in 74 % yield. A final Suzuki-Miyaura coupling of 
the 5-iodo imidazole 13 with pyridine-4-boronic acid followed by TBAF deprotection gives the 
dialkynyl-imidazole 14. Mild thermolysis of 14 at 80° C under acidic conditions in the presence 








CuI (5 mol %)
(20 mol %)
Cs2CO3 (2 equiv)
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Scheme 2.3. Synthesis of dialkynylimidazoles. Reagents and conditions: (a) BrCCTIPS, CuI, 
AcC, Cs2CO3, dioxane, 50 °C overnight followed by reflux for 4 h (79 %, 1:9 10a/10b); (b) i) n-
BuLi, ii)  I2, THF, -78 °C (91 %); (c) TIPSOCH2CH2CCH, Pd(PPh3)4, CuI, Et3N (73 %); (d) i) n-
BuLi, ii) I2, THF, -78 °C (74 %); (e) pyridine 4-boronic acid, Pd(PPh3)4, K2CO3 (41 %); (f) 
TBAF, THF, -78 °C (89 %); (g) Me4NCl, TfOH, DMF, 80 °C, 5 days (50 %).  
  
38 
2.3. P38INHIBITION STUDIES OF 1,2-DIALKYNYLIMIDAZOLES  
All kinase inhibition studies were performed by Invitrogen using the Z’-Lyte
TM
 assay at 
[ATP] = Km[app] and protein substrate concentration of 20 M. These 1,2-dialkynylimidazoles 
were assayed against p38α MAPK at a fixed time-point of 60 min (Table 2.1). Compounds 7a–c 
and 8a–c display modest inhibition at 10 μM concentration. In this series there is little difference 
in activity between the 1-alkynyl-5-fluorophenyl regioisomers 7a–c and the 1-alkynyl-5-
pyridylisomers 8a–c, in contrast to reported 1-substituted pyridylimidazole p38α inhibitors (21). 
Interestingly, the 1-ethynylsubstituted analog 14 is a potent inhibitor of p38α. Compound 14 
completely inhibits p38α at 10 μM (Table 2.1), and has an IC50 for p38α of 200 nM. The 
inhibition due to 14 in these assays is primary due to non-covalent inhibition. Pre-incubation of 
the kinase with 14 for 60 min prior to the addition of ATP did not change the IC50 value. In 
comparison, the IC50 of 14 against p38 (5.4 μM) is >25-fold higher. Dialkyny-limidazole 14 
was also assayed at concentration of 20 μM against a panel of 53 additional human kinases 
(Table 2.2). Only one kinase, (MAPK4/HGK) was strongly inhibited (> 90 % inhibition at 20 
μM, IC50 = 4.2 μM), while six additional kinases were moderately inhibited (between 50–90 % 
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               7b 63 
 
               8b 83 
 
               7c 53 
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Tests were carried out in duplicates.  































ABL1 15 MAP4K4 (HGK) 92 
ACVR1B (ALK4) 72 MAPK1 (ERK2)  6 
AKT1 (PKBα) 29 MAPK12 (p38) 14 
AMPK A1/B1/G1           -11 MAPK13 (p38) 12 
AURKA (Aurora A)  7 MAPK8 (JNK1) 21 
BTK  9 MAPK9 (JNK2) 88 
CDK1/cyclin B  3 MAPKAPK2  3 
CHEK1 (CHK1)  5 MARK2 14 
CSNK1G2 (CK1 ) 36 MET (cMet) 11 
CSNK2A1 (CK2 1)  3 NEK1 11 
DYRK3  8 NTRK1 (TRKA)  1 
EGFR (ErbB1) 84 PAK4  8 
EPHA2 23 PDGFRB (PDGFR) 10 
ERBB2 (HER2) 41 PHKG2            -15 
FGFR1  8 PIM1  3 
FLT3 17 PLK1  7 
FRAP1 (mTOR)  6 PRKACA (PKA) 50 
GSK3B (GSK3β) 44 PRKCB1 (PKC I) 80 
IGF1R -1 RAF1 (cRAF)  82 
IKBKB (IKKβ) 5 RET 21 
INSR 7 ROCK1 15 
IRAK4 1 RPS6KA3 (RSK2)  0 
JAK3 4 RPS6KB1 (p70S6K)  7 
KDR (VEGFR2)           36 SRC 27 
KIT 5 SYK  3 
LCK           48 TEK (Tie2)  5 







Average of two separate trials. 






2.4. COVALENT ADDUCTION OF P38 BY 1,2-DIALKYNYLIMIDAZOLES  
To examine whether 1,2-dialkynylimidazoles covalently modify p38, 14 (100 μM) was 
incubated with non-phosphoryated p38α (5 μM) at 37 °C in 50 mM HEPES, 10 mM MgCl2, 2 
mM DTT, 1 mM EGTA, pH 7.5 for 12 h, followed by extensive dialysis, and the sample was 
analyzed by ESI-MS. A new peak in the mass spectrum at m/z = 41896, which corresponds to 
addition of a single molecule of 14 (MW = 331) to p38α, was observed (~25 % adduct) (Figure 
2.3). Under identical conditions but with 1 mM DTT present, the adduct was the predominant 
species observed (Figure 2.4). On the contrary, in the presence of 4 mM DTT, the adduct 























       
Figure 2.3. ESI-MS spectra of p38 and modified p38 by compound 14. (a) Unphosphorylated 
p38 incubated for 12 h at 37 °C; (b) Unphosphorylated p38 incubated with 





p38 with 1 mM DTT: 
 
 
p38 with 4 mM DTT: 
 
Figure 2.4. ESI-MS spectra of modified p38by compound 14 in the presence of 
DTTUnphosphorylatedp38wasincubated with 14 in the presence of 1 mM or 4 mM DTT for 






2.5. HEPATOTOXICITY STUDIES OF 1,2-DIALKYNYLIMIDAZOLES 
A common concern for pyridinylimidazole MAPK inhibitors such as RWJ 67657 and 
SB-203580 is their inhibition of cytochrome P450 (CYP450) enzymes, which may be linked to 
hepatotoxicity (22). Interestingly, the dialkynylimidazole 14 displays a much lower level of 




Compound % inhibition (CYP450, 2D6) 










SB-203580 78 97 
 














In summary, novel p38α-targeting dialkynylimidazoles were designed, synthesized and 
evaluated. Although 1-phenethynyl-substituted dialkynylimidazoles 7a–c and 8a–c are only 
modest inhibitors of p38α, the 1-ethynyl-substituted dialkynylimidazole 14 is a potent and 
selective inhibitor. Commensurate with the increased facility of rearrangement of 1-
ethynylsubstituted dialkynylimidazols relative to 1-phenethynyl analogues, compound 14 forms 
a covalent adduct with p38α (23). However, the conditions for p38α adduct formation (12 h at 37 
°C) are much milder than those required for cyclization/trapping of 14 to afford 15 (5 days at 80 
°C), indicating that the kinase may facilitate the cyclization of 14. Further studies on the site and 
mechanism of this covalent modification of p38α by 1-ethynyl-substituted dialkynylimidazoles 
are on-going. The unique kinase inhibition, covalent kinase adduct formation, and minimal 
CYP450 2D6 inhibition by compound 14 demonstrate that dialkynylimidazoles are a new, 













2.7. EXPERIMENTAL SECTION 
General: All reactions were carried out under argon in oven-dried glassware with magnetic 
stirring. Unless otherwise noted, all commercial chemicals were used without further 
purification. Tetrahydrofuran (THF), 1,4-dioxane, and diethyl ether (Et2O) was distilled from 
sodium/benzophenone prior to use. Dichloromethane (CH2Cl2) and triethylamine (Et3N) was 
distilled from CaH2 prior to use. CuI was purified by recrystallization. Unless otherwise noted, 
organic extracts were dried with Na2SO4, filtered through a fritted glass funnel, and concentrated 
with a rotary evaporator (20-30 mmHg). Flash chromatography was performed with silica gel 
(230-400 mesh) using the mobile phase indicated. Melting points (open capillary) are 




C NMR spectra were determined in DMSO or 
CDCl3 on a spectrometer operating at 400 and 100 MHz, respectively, and are reported in ppm 
using solvent as internal standards (7.26 ppm for 
1
H and 77.0 ppm for 
13
C). Unless otherwise 
noted, all mass spectra were obtained in the positive mode by chemical ionization using methane 

















A 250 mL three-necked round bottom flask was charged with 4(5)-(4-fluorophenyl)-5(4)-(4-
pyriyl)imidazole (0.87 g, 3.64 mmol). To the flask was added anhydrous CH2Cl2 (29 mL) 
followed by drop-wise addition of a solution of Et3N (1.01 mL, 7.27 mmol) and triphenylmethyl 
chloride (1.22 g, 4.36 mmol). After the reaction mixture was stirred for 12 h, to the reaction flask 
CH2Cl2 (50 ml) and water (50 ml) were added. The resulting mixture was extracted with CH2Cl2 
three times. The combined extracts were washed three times with brine, dried, concentrated and 
subjected to flash chromatography (100 % EtOAc) to afford 4-(4-pyridyl)-5-(4-fluorophenyl)-1-
trityl-1H-imidazole (1.0 g, 58 % yield) as a white solid: mp 191-192 ºC; 
1
H NMR (CDCl3) δ 8.30 
(dd, 2 H, J = 1.6, 3.2 Hz ), 7.78 (s, 1H), 7.26-7.23 (m, 9H), 7.13-7.11 (m, 6H), 7.09 (dd, 2H, J = 
1.6, 3.2 Hz), 6.55-6.50 (m, 2H), 6.45-6.41 (m, 2H); 
13
C NMR (CDCl3) δ: 162.3 (d, J = 248.5 
Hz), 149.8 (2C), 142.1 (3C), 141.5 (2C), 139.4, 138.9, 134.0 (d, 2C, J = 8.9 Hz), 131.4, 130.6 
(6C), 128.2 (3C), 128.1 (6C), 127.0 (d, J = 3.7 Hz), 120.9, 115.1 (d, 2C,  J = 21.6 Hz), 76.1; MS 
m/z: HRMS (ESI) calcd for C33H25N3F (M
+















A 50 mL three-necked round bottom flask was charged with 2 (212.3 mg, 0.44 mmol) and dry 
THF (5.5 ml). To the flask was added n-BuLi (0.256 mL, 2.06 M in hexane, 0.53 mmol) at 0 ºC. 
The solution, which gradually turned red, was stirred at room temperature for 15 min. The 
solution was then cooled to 0 ºC, and I2 (89.4 mg, 0.35 mmol) was added to the reaction flask. 
The reaction mixture was stirred for 10 min at room temperature, and H2O (5.5 ml) was poured 
into the reaction mixture. The solution was concentrated, extracted with CH2Cl2, dried and 
subjected to flash chromatography (50:50 EtOAc/hexane) to afford 4-(4-pyridyl)-5-(4-
fluorophenyl)-1-trityl-2-iodo-1H-imidazole (160 mg, 60 % yield) as a white solid: mp = 145-146 
ºC;
 1
H NMR  (CDCl3) δ: 8.28 (dd, 2H, J = 1.6, 3.0 Hz), 7.23-7.09 (m, 15 H), 6.99 (dd, 2H, J = 
1.6, 3.0 Hz), 6.68-6.59 (m, 4H); 
13
C NMR (CDCl3) δ: 161.9 (d, J = 247.7 Hz), 149.3 (2C), 141.6 
(2C), 140.9 (3C), 140.2, 135.7, 132.8 (d, 2C, J = 8.2 Hz), 131.4 (6C), 128.0, 127.9 (3C), 127.5 
(6C), 120.9, 115.4 (d, 2C, J = 21.5 Hz), 94.6, 79.1; MS m/z: HRMS (ESI) calcd for C33H24N3FI 
(M
+















A 50 mL three-necked round bottom flask was charged with 3 (300 mg, 0.5 mmol) and THF (7 
ml). To the flask were added TFA (1.0 equiv) and H2O (2.0 equiv). After the reaction mixture 
was stirred for 4 h, to the reaction flask was added saturated aqueous NaHCO3 (5 ml). The 
reaction mixture was extracted with CH2Cl2 several times. The combined extracts were dried, 
concentrated and subjected to flash chromatography (100 % EtOAc) to afford 4-(4-pyridyl)-5-(4-
fluorophenyl)-2-iodo-imidazole (152 mg, 83 % yield) as a yellow solid: mp = 148.5-149.8 ºC; 
1
H 
NMR (DMSO-d6 + TFA) δ: 8.68 (d, 2H, J = 6.6 Hz), 7.88 (d, 2H, J = 6.6 Hz), 7.60-7.57 (m, 
2H), 7.39-7.35 (m, 2H); MS m/z: HRMS (CI) calcd for C14H10N3FI (M
+




























4-(4-fluropheynyl)-5-(4-pyridyl)-2-iodo-1-(phenylethynyl)-1H-imidazole (5) and 4-(4-
pyridyl)-5-(4-fluorophenyl)-2-iodo-1-(phenylethynyl)-1H-imidazole (6): 
To a solution of 4 (185.4 mg, 0.51 mmol) in dry THF (4 ml) at 0 ºC was added LHMDS (0.51 
ml, 1 M in hexanes). After stirring at 0 ºC for 30 min, the solution was transferred via cannula to 
a solution of phenyl(phenylethynyl)-iodinium tosylate (369.3 mg, 0.78 mmol) in CH2Cl2 (4 ml). 
After stirring at room temperature for 2 h, to the reaction flask was added H2O (10 ml), the 
aqueous layer was extracted with CH2Cl2 three times and the combined organic layers were dried 
and evaporated. The residue was purified by flash chromatography (50:50 EtOAc/hexane) to 
afford 5 (17 mg, 7 % yield) as a yellow solid: mp 157.5-161.7 ºC; 
13
C NMR (CDCl3) δ: 163.7 (d, 
J = 250.0 Hz), 149.5 (2C), 140.3, 138.0, 135.0, 132.2 (d, 2C, J = 8.9 Hz), 131.3 (2C), 129.3, 
128.5 (2C), 124.0, 120.9 (2C), 120.5, 116.4 (d, 2C, J = 21.6 Hz), 95.1, 78.1, 77.2; MS (m/z): 
HRMS (CI) calcd for C22H14N3FI (M
+
) 466.0217, found 466.0216, and 6 (20 mg, 8 % yield) as a 
yellow solid: mp 181.0-184.8 ºC; 
1
H NMR (CDCl3) δ: 8.50 (br, 2H), 7.62-7.51 (m, 2H), 7.41 (d, 
2H, J = 6 Hz), 7.36-7.32 (m, 5H), 7.24-7.20 (m, 2H); 
13
C NMR (CDCl3) δ: 163.6 (d, J = 250.0 
Hz), 149.9 (2C), 139.9, 138.2, 134.8, 132.2 (d, 2C, J = 8.2 Hz), 131.3 (2C), 129.3, 128.5 (2C), 
124.0 (d, J = 2.9 Hz), 120.8 (2C), 120.5, 116.3 (d, 2C, J = 21.6 Hz), 95.0, 78.0, 77.2; MS m/z: 
HRMS (CI) calcd for C22H14N3FI (M
+














To a solution of 6 (45 mg, 0.097 mmol) in Et3N (1.2 ml) was added the terminal alkyne (0.12 
mmol), Pd(PPh3)4 (5.6 mg, 0.005 mmol) and CuI (1.9 mg, 0.01 mmol). The reaction mixture was 
stirred at room temperature until 5 was completely consumed. The reaction mixture was filtered. 
The filtrate was evaporated, and the residue was purified by flash chromatography (0-25 % 
EtOAc/hexane) to afford the silylated dialkynylimidazole (6 mg, 0.01 mmol). To this material in 
THF (2 ml) at -78 °C was added TBAF (0.015 ml of 1 M solution in THF, 0.015 mmol), and the 
reaction mixture was stirred at -78 °C until completion. The reaction mixture was quenched with 
water (2 ml) and extracted with CH2Cl2 three times. The organic layers were combined, dried 
over Na2SO4 and the solvent was evaporated under reduce pressure. The residue was purified by 
flash chromatography (0-25 % EtOAc/hexane) to afford 5-(4-fluorophenyl)-4-(4-pyridyl)-1-
(phenylethynyl)-2-ethynyl-1H-imidazole 3 mg (yield 9 %) 7a as a yellow solid: mp = 171.1-
173.5 ºC;
 1
H NMR (CDCl3) δ: 8.53 (br, 2H), 7.55-7.50 (m, 2H), 7.46 (br, 2H), 7.38-7.33 (m, 
5H), 7.25-7.19 (m, 2H), 3.53 (s, 1H); MS m/z: HRMS (CI) calcd for C24H15N3F (M
+
) 364.1250, 











4-(4-fluorophenyl)-5-(4-pyridyl)-1-(phenylethynyl)-2-ethynyl-1H-imidazole (8a):  
Following the general procedure described, 8a (16 % yield) was obtained as a yellow solid: mp 
138.4-141.4 °C (dec); 
1
H  (CDCl3) δ: 8.72 (d, 2H, J = 4.0 Hz), 7.53-7.46 (m, 4H), 7.43-7.33 (m, 



























Following the general procedure described, 7b (77 % yield) was obtained as a yellow solid: mp 
181-185 °C (dec); 
1
H (CDCl3) δ: 8.50 (d, 2H, J = 3.0 Hz), 7.53-7.50 (m, 2H), 7.44 (d, 2H, J = 3.0 
Hz), 7.50-7.34 (m, 5H), 7.24-7.19 (m, 2H); 4.61 (s, 2H); MS m/z: HRMS (CI) calcd for 
C25H17N3OF (M
+























Following the general procedure described, 8b (48 % yield) was obtained as a yellow solid: mp: 
181-184 °C; 
1
H  (CDCl3) δ: 8.71 (dd, 2H, J = 1.6 Hz, 3.2 Hz), 7.51-7.44 (m, 4H), 7.41-7.33 (m, 
5H), 7.02-6.98 (m, 2H), 4.61 (s, 2H); 
13
C NMR (CDCl3) δ: 162.7 (d, J = 247.7 Hz), 150.3 (2C), 
139.1, 136.2, 135.1, 131.4 (2C), 129.6 (d, 2C, J = 8.2 Hz), 129.3, 128.6 (2C), 128.1 (d, J = 3.0 
Hz), 127.0, 124.0, 120.5 (2C), 115.7 (d, 2C, J = 21.6 Hz), 94.6, 77.4, 76.0, 73.6, 51.2; MS m/z: 
HRMS (CI) calcd for C25H17N3OF (M
+






















Following the general procedure described, 7c (40 % yield) was obtained as a yellow solid: mp 
163-165 °C; 
1
H (CDCl3) δ: 8.49 (dd, 2H, J = 1.6 Hz, 3.2 Hz), 7.52-7.49 (m, 2H), 7.43 (dd, 2H, J 
= 1.6 Hz, 3.2 Hz), 7.36-7.33 (m, 5H), 7.23-7.19 (m, 2H), 3.90 (t, 2H, J = 6.4 Hz), 2.83 (t, 2H, J = 
6.4 Hz); 
13
C NMR (CDCl3) δ: 163.6 (d, J = 249.9 Hz), 149.9 (2C), 140.2, 135.0, 134.9, 132.2 (d, 
2C, J = 8.2 Hz), 131.3, 131.3, 129.2 (2C), 128.6 (2C), 123.9, 121.1 (2C), 120.7, 116.3 (d, 2C, J = 
21.6 Hz), 94.0, 77.2, 76.2, 70.9, 60.5, 24.0; MS m/z: HRMS (CI) calcd for C26H19N3OF (M
+
) 























Following the general procedure described, 8c (40 % yield) was obtained as a yellow solid: mp: 
163.3-165.5 °C; 
1
H (CDCl3) δ: 8.71 (br, 2H), 7.51-7.47 (m, 2H), 7.45 (d, 2H, J = 5.2 Hz), 7.40-
7.35 (m, 5H), 7.02-6.98 (m, 2H), 3.89 (t, 2H, J = 6.2 Hz), 2.83 (t, 2H, J = 6.2 Hz); MS m/z: 
HRMS (CI) calcd for C26H19N3OF (M
+


























   
4-(4-fluorophenyl)-1-(2-triisopropylsilanylethynyl)-1H-imidazole 10b: A reaction flask under 
argon was charged with Cs2CO3 (652 mg, 2 mmol), CuI (10 mg, 0.05 mmol), and 4-
fluorophenyl-imidazole (20) (162 mg, 1 mmol) and backfilled with argon. Dry 1,4-dioxane (2 
mL) was added followed by the bromophenylacetylene (0.237 mL, 2 mmol), the 2-
acetylcyclohexanone (0.026 mL, 0.2 mmol), and 4 Å molecular sieves (75-115 mg). The mixture 
was heated to 50 °C in an oil bath for 14 h and then heated to reflux for 4 h. The reaction mixture 
was cooled to room temperature, quenched with 5 mL of a saturated NH4Cl solution, and 
extracted with CH2Cl2 (3× 20 mL). The combined organic layers were evaporated and (flash 
chromatography; 0–10 % EtOAc/hexane), 246 mg of 15a (72 %) was obtained as an orange 
solid: mp = 29.5–30.7 °C; 
1
H NMR δ 7.76 (1H, d, J = 1.2 Hz), 7.75-7.70 (2H, m), 7.32 (1H, d, J 
= 1.2 Hz), 7.08-7.03 (2H, m), 1.14-1.12 (21H, m); 
13
C NMR δ 162.3 (d, J = 245.5 Hz), 140.8, 
140.3, 128.9 (d, J = 2.9 Hz), 126.8 (2C, d, J = 8.2 Hz), 116.5, 115.5 (2C, d, J = 21.6 Hz), 91.5, 
70.1, 18.5 (6C), 11.1 (3C); IR (KBr) 3145, 2945, 2893, 2866, 2195, 2164, 1564, 1501, 1463, 
















TIPS   
 
5-(4-fluorophenyl)-1-(2-triisopropylsilanylethynyl)-1H-imidazole 10a:  
Also isolated from the chromatography referred to above was 23 mg of 10a (7 %) obtained as a 
yellow liquid: 
1
H NMR δ 7.83 (1H, s, br), 7.65-7.61 (2H, m), 7.12-7.06 (3H, m), 1.14-1.01 (21H, 
m); IR (neat) 3082, 2945, 2866, 2194, 2159, 1600, 1564, 1504, 1468, 1384, 1291, 1236, 1196, 
1161, 1102, 1015cm-1; MS (m/z): HRMS calc for C20H28FN2Si (M
+























4-(4-fluorophenyl)-2-iodo-1-((triisopropylsilyl)ethynyl)-1H-imidazole (11): To a solution of 
10b (216 mg, 0.63 mmol) in THF (5.5 ml) was added n-BuLi (0.30 ml of 2.5 M solution in 
hexane, 0.75 mmol). The reaction mixture was stirred for 3 h at -78 °C. To the reaction flask was 
added I2 (160 mg, 0.63 mmol). After stirring for 1 h at -78 °C, the reaction mixture was 
quenched with saturated Na2S2O3 solution and the temperature was cooled to room temperature. 
The reaction mixture was extracted with CH2Cl2 several times. The combined organic layers 
were dried over Na2SO4 and the solvent was evaporated under reduce pressure. The residue was 
purified by flash chromatography (0-5 % EtOAc/hexane) to afford 4-(4-fluorophenyl)-2-iodo-1-
((triisopropylsilyl)ethynyl)-1H-imidazole (267 mg, 91 % yield) as a yellow oil 11: 
1
H NMR 
(CDCl3) δ: 7.72-7.68 (m, 2H), 7.45 (s, 1H), 7.08-7.04 (m, 2H), 1.18-1.13 (m, 21H); 
13
C NMR 
(CDCl3) δ: 162.5 (d, J = 245.5 Hz), 143.9, 128.1 (d, J = 3.0 Hz), 126.8 (d, 2C, J = 8.2 Hz), 
120.1, 115.6 (d, 2C, J = 21.6 Hz), 94.6, 91.5, 75.0, 18.6 (6C), 11.2 (3C);  MS m/z: HRMS (CI) 
calcd for C20H27N2FSiI (M
+















imidazole (12): To a solution of 11 (0.82 g, 1.45 mmol) in Et3N (20 ml) was added 
triisopropyl(pent-3-ynyloxy)silane (0.36 ml, 0.12 mmol), Pd(PPh3)4 (84 mg, 0.073 mmol) and 
CuI (29 mg, 0.152 mmol). The reaction mixture was stirred at room temperature until 5 was 
completely consumed. The reaction mixture was filtered. The filtrate was evaporated, and the 
residue was purified by flash chromatography (0-5 % EtOAc/hexane) to afford 4-(4-
fluorophenyl)-1-((triisopropylsilyl)ethynyl)-2-(4-(triisopropylsilyloxy)but-1-ynyl)-1H-imidazole 
(0.60 g, 73 % yield) as a yellow oil: 
1
H NMR (CHCl3) δ 7.75-7.71 (m, 2H), 7.28 (s, 1H), 7.07-
7.03 (m, 2H), 3.91 (t, 2H, J = 8.0 Hz), 2.71 (t, 2H, J = 8.0 Hz), 1.18-1.07 (m, 42 H); 
13
C NMR 
(CHCl3): δ 162.4 (d, J = 245.5 Hz), 140.3, 135.6, 128.4 (d, J = 3.0 Hz), 126.9 (d, 2C, J = 8.2 
Hz), 116.5, 115.5 (d, 2C, J = 21.6 Hz), 92.6, 90.9, 72.8, 70.4, 61.5, 23.7, 18.5 (6C), 17.8 (6C), 
11.8 (3C), 11.1 (3C);  MS m/z: HRMS (CI) calcd for C33H51N2OSi2IF (M
+

















ynyl)-1H-imidazole (13): To a solution of 12 (35 mg, 0.062 mmol) in THF (0.9 ml) was added 
n-BuLi (0.025 ml of 2.5 M solution in hexane, 0.0625 mmol). The reaction mixture was stirred 
for 30 min at -78 °C. To the reaction flask was added I2 (16 mg, 0.062 mmol). After stirring for 
10 min at -78 °C, the reaction mixture was quenched with saturated Na2S2O3 solution and the 
temperature was cooled to room temperature. The reaction mixture was extracted with CH2Cl2 
several times. The combined organic layers were dried over Na2SO4 and the solvent was 
evaporated under reduce pressure. The residue was purified by flash chromatography (0-1 % 
EtOAc/hexane) to afford 4-(4-fluorophenyl)-5-iodo-1-((triisopropylsilyl)ethynyl)-2-(4-
(triisopropylsilyloxy)but-1-ynyl)-1H-imidazole (32 mg, 74 % yield) as an orange oil 13: 
1
H 
NMR (CDCl3) δ: 7.96-7.92 (m, 2H), 7.12-7.08 (m, 2H), 3.90 (t, 2H, J = 7.8 Hz), 2.73 (t, 2H, J = 
7.8 Hz). 
13
C NMR (CHCl3) δ 162.6 (d, J = 247.0 Hz), 143.3, 137.2, 129.1 (d, 2C, J = 8.1 Hz), 
128.4, 115.2 (d, 2C, 21.6 Hz), 94.1, 90.3, 77.8, 70.5, 70.4, 61.5, 23.8, 18.6 (6C), 18.0 (6C), 11.9 
(3C), 11.2 (3C); MS m/z: HRMS (CI) calcd for C33H51N2OSi2IF (M
+














4-(4-fluorophenyl)-5-(4-pyridyl)-1-(ethynyl)-2-(but-3-yn-1-ol)-1H-imidazole (14):  
A mixture of 13 (89 mg, 0.13 mmol), 4-pyridine-boronic acid (19.3 mg, 0.16 mmol), Pd(PPh3)4 
(15 mg ,0.013 mmol), toluene (2.1 ml), methanol (0.16 ml) and 2M potassium carbonate (0.16 
ml) was refluxed for 4 days under argon. After the reaction mixture was cooled to room 
temperature, the mixture was filtered. The filtrate was evaporated, and the residue was purified 
by flash chromatography (0-10 % EtOAc/hexane) to afford the silylated dialkynylimidazole (34 
mg, 41 % yield). To this material in THF (1.3 ml) at -78 °C was added TBAF (0.05 ml of 1 M 
solution in THF, 0.05 mmol), and the reaction mixture was stirred at -78 °C until completion. 
The reaction mixture was quenched with water (2 ml) and extracted with CH2Cl2 three times. 
The organic layers were combined, dried over Na2SO4 and the solvent was evaporated under 
reduce pressure. The residue was purified by flash chromatography (50-100 % EtOAc/hexane) to 
obtain 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(ethynyl)-2-(but-3-yn-1-ol)-1H-imidazole (16 mg, 89 
% yield) as a light yellow solid: mp 120.8-123.8 °C (dec); 
1
H NMR (CHCl3) δ 8.50 (d, 2H, J = 
5.4 Hz), 7.42-7.39 (m, 2H), 7.35 (d, 2H, J = 5.4 Hz), 6.98-6.94 (m, 2H), 3.88 (t, 2H, J = 6.4 Hz), 
3.24 (s, 1H), 2.79 (t, 2H, J = 6.4 Hz); 
13
C NMR (CHCl3) δ 162.6 (d, J = 247.0 Hz), 150.3 (2C), 
138.2, 136.1, 136.0, 129.5 (d, 2C, J = 8.2 Hz), 128.0 (d, J = 3.7 Hz), 126.6, 123.9 (2C), 116.6 (d, 
2C, J = 21.5 Hz), 94.8, 70.4, 69.6, 65.5, 60.3, 23.9; MS m/z: HRMS (CI) calcd for C20H15N3OF 
(M
+
) 332.1196, found 332.1194. Anal. Calcd for C20H15N3OF: C, 72.50; H, 4.26; N, 12.68. 












2-(4-Fluorophenyl)-3(4-pyridinyl)-5-chloro-7-ethanol-imidazo[1,2-α]-pyridine (15): To a 
solution of 14 (18 mg, 0.054 mmol) in dry DMF (1.74 ml) was added tetramethylammonium 
chloride (5.89 mg, 0.054 mmol) and TFA (4.16 µl, 0.054 mmol). The mixture was stirred at 80 
ºC for 5 days. The solvent was removed and the residue was purified by flash chromatography 
(100 % EtOAc) to afford 2-(4-fluorophenyl)-3(4-pyridinyl)-5-chloro-7-ethanol-imidazo[1,2-α]-
pyridine (10 mg, 50 % yield) as a yellow solid: mp 180.8 -181.5 ºC; 
1
H NMR (CDCl3) δ 8.70 
(br, 2 H), 7.52 (s, 1H), 7.41-7.38 (m, 4H), 6.97-6.92 (m, 2H), 6.78 (d, 1H, J = 0.8 Hz), 3.95 (t, 
2H, J = 6.2 Hz), 2.91 (t, 2H, J = 6.2 Hz); 
13
C NMR (CDCl3) δ: 162.6 (d, 2C, J = 247.0 Hz), 
149.3, 147.0, 143.7, 140.0, 138.0, 130.1 (d, 2C, J = 8.2 Hz), 129.1 (d, 2C, J = 3.7 Hz), 127.5, 
126.4, 119.0, 116.4, 115.4 (d, 2C, J = 20.8 Hz), 115.3, 62.1, 38.1; MS m/z: HRMS (CI) calcd for 









Covalent adduction of p38 by 14: 
 
The reaction consists of 5 µM p38-alpha, 100 µM 14 in 50 mM HEPES, pH 7.5, 1 mM EGTA, 
various concentrations DTT (1 mM, 2 mM, 4 mM), 10 mM MgCl2. After 12 h incubation, the 
reaction mixture was dialyzed in 1 Liter of 25 mM HEPES, pH 7.5, 1 mM DTT, 50 mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA, 10 % (v/v) glycerol. After 12 h dialysis, the protein was 
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Targeting kinase docking sites: a fluorescence-based assay for p38 inhibitors 
targeting a substrate binding site 
 
3.1. INTRODUCTION 
The mitogen-activated protein kinases (MAPKs) are serine/theronine kinases that serve 
as important mediators of inflammatory cytokines including tumor necrosis factor alpha (TNFα) 
and interleukin-1 beta (1L-1β) (1, 2). The vast majority of MAPK inhibitors reported to date 
target the highly conserved ATP binding sites of these enzymes. However, using the ATP 
binding site as a drug target has several limitations. For example, the ATP binding site is highly 
conserved among kinases. Thus, it is challenging to discover highly selective small molecules. 
Moreover, intracellular ATP is typically present at a concentration of 1mM, leading to a 
discrepancy between IC50 values measured by biochemical versus cellular assays (3, 4). In 
addition to ATP-competitive inhibitors, a few small molecules have been found to exploit a new 
hydrophobic pocket, which is adjacent to the ATP binding site. The hydrophobic pocket is 
created by the activation loop which contains the conserved DFG motif. Upon binding to these 
inhibitors, the DFG motif undergoes a conformational change, which causes the residue Phe169 
to move from a buried conformation (DFG-in) to a solvent exposed conformation (DFG-out) (5).  
Recently, there has been a growing interest in developing drug candidates against more 
variable substrate docking sites. At least two types of docking interactions between MAPKs and 
their substrates, activators and phosphatases have been identified (6). In both docking 
interactions, short motifs are found within substrates: the D domain (D site, domain, DEJL 
domain) and the DEF domain (Docking site for ERK, FXFP, F site or DEF site); a 
complementary pocket or groove is found on the kinase. In particular, the interactions between 
68 
MAPK and D domains have been characterized by mutagenesis, hydrogen exchange-mass 
spectrometry, and X-ray crystallography (7, 8). The D domain consists of a cluster of basic 
residues, a short spacer and a hydrophobic patch (Lys/Arg-Lys/Arg-Xaa2-6--X-, where  is a 
hydrophobic residue, such as Leu, Iso, or Val) (9).  The complementary D-recruitment site 
(DRS) on MAP kinase is composed of acidic patch in the C-terminal known as the CD (Common 
Docking) domain (10) and hydrophobic docking groove (11, 12) (or referred to as “ED) (9). 
MAPK substrate specificity has been shown to be mediated through docking interactions 
involving substrate docking motifs that interact with kinase docking sites (7, 13-15). Blocking 
docking interactions between kinase network partners is a promising alternative approach for 
selectively inhibiting kinase (and/or phosphatase) signaling.  First, this approach can overcome 
the limitations of targeting ATP-binding sites. Second, since protein kinases achieve high 
biological specificity by recognizing their targets through docking interactions, disrupting this 
interaction can result in specific individual kinase inhibition. Additionally, many protein 
phosphatases also bind to substrates and regulators in the same manner (16). It has been reported 
that small molecule inhibitors that target calcineurin phosphatase activity showed success by 
disrupting docking interactions (17). 
In the past decade, many efforts have been made to design specific docking peptide 
inhibitors (18). For instance, cell-permeable docking peptides were shown to selectively 
modulate MAPK and PP1 activity in vivo (19-21). Recently, Bardwell et al. reported that MKK 
D-sites have a greater preference for binding to their cognate MAPKs than to non-cognate 
MAPKs with a 10-fold difference. In their study, D-site peptide derived from MKK3 is a highly 
selective and potent inhibitor of p38α (22). Although docking peptide inhibitors offer high 
specificity, and often low concentration of peptide inhibitors are required to compete with 
peptide or protein substrates, they also encounter common problems including metabolic 
instability and inability to cross cell membranes (23). So far, small molecules that target the 
substrate binding site of MAPKs have remained largely unexplored. An approach to docking-
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based drug design is to use high-throughput experimental and computational structure-based 
screens (16).  
Here we report the identification of dialkynylimidazoles as a new class of small 
molecule, covalent p38α MAP kinase docking site probes. We propose that a mechanism 
involving the nucleophilic addition of a docking site cysteine thiol to the N-ethynyl group of the 
probe. We further demonstrate that such probes can be used to fluorescently label p38α both in 
vitro and in cells via azide-alkyne “Click” chemistry. This serves as the basis of an assay that can 





3.2. COVALENT ADDUCTION OF P38BY N-ALKYNYLIMIDAZOLE  
In our prior work, we showed that the 1,2-dialkynylimidazole 1 forms a covalent adduct 
with p38α at 37 °C (25 % abundance) (24). In a study of related N-alkynylimidazoles, we 
discovered that N-alkynylimidazole 2 also covalently modifies p38α (Figure 3.1). First, N-
alkynylimidazole 2 was prepared from previously reported 4-(4-fluorophenyl)-5-(4-pyridyl)-1-
(2-triisopropylsilanyl)imidazole (25), followed by silyl deprotection with TBAF in THF. Next, 
non-phosphorylated p38α (5 M) was incubated with 2 (100 M) at room temperature in 50 mM 
HEPES, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, pH 7.5 for 12 h, followed by extensive 
dialysis, and the sample was analyzed by ESI-MS (Figure 3.2). A new peak in the mass spectrum 
at m/z = 41824, which corresponds to addition of a single molecule of 2 (MW = 263 Da) to p38α, 
was observed (100 % abundance). 
 In order to identify the site of adduction, the sample was digested with chymotrypsin and 
further analyzed by MALDI-MS/MS. The MASCOT generated chymotrypsin digest coverage 
based on MS values showed 88 % coverage of the protein in the untreated sample (p38α alone), 
with peptides 36-59, 130-132, 208-216, 271-274 unobserved. For the treated digest (modified 
p38α by compound 2), the coverage was 83 %, with peptides 36-59, 105-132, 208-216 
unobserved. The major difference in coverage was the absence of peptide 105-129 in the treated 
sample. Comparative MALDI analysis and de novo sequencing identified the modification site. 
In the untreated sample, the peptide 104-129 is seen at 2952.476, with sequence confirmed by 
MS/MS. This peptide is absent from the treated sample. However, a new peptide is observed at 
3215.553 (Figure 3.3). De novo sequencing identified the peptide as residues 104-129 with 
modification of Cys119 by a mass addition of 263 Da (Figure 3.4). The modification at Cys119 
was observed in five additional peptide sequences for peptides only in the treated sample. They 
were observed with same modification of 263 Da, and at lower signal intensity with modification 
of 261 Da: residues 115-119 at 965.435/967.450, 110-119 at 1435.6/1437.660, 115-129 at 
2048.960/2050.976, 111-129 at 2464.155, and 110-129 at 2519.171/2521.178. However, none of 
these peptides were observed in the untreated sample. The MS of the treated protein 
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chymotrypsin digest does not contain peptide 104-129 in an unlabeled form, only the labeled 
peptide, implying that this site is modified stoichiometrically. Thus, it is unlikely that any other 
site on the protein is modified. As a control, a common cysteine alkylating agent, iodoacetamide, 
was incubated with p38α under the same conditions except that TCEP was used as a reducing 
agent. New peaks corresponding to multiple additions of iodoacetamide were observed by ESI-
MS (Figure 3.5).  
After we determined the site of modification by compound 2, we studied the X-ray 
crystal structure of p38α. Cys119 residue is located in the D-recruitment site (DRS) facing the 
pocket (Figure 3.6) (26). This groove appears to be a potential druggable site. First, it has a 
significant hydrophobic pocket that favors small molecule interaction. Second, this groove also 
contains polar residues, and polar groups in the binding site were shown to play an important 
role in the recognition of drug-like molecules (27). Furthermore, this pocket is not conserved 
within MAPK family (28, 29). Wang et al reported that four amino acids in the p38α surface 
groove may determine substrate specificity: Asn114, Cys119, Lys121 and Gly219 (26). More 
importantly, targeting this site with small molecules will potentially result in disruption of 
protein-protein interaction, thereby inhibiting kinase activity. Additionally, we were also 
intrigued by the result that the N-alkynylimidazole 2 selectively modifies Cys119, despite the 
presence of three other Cys residues in its primary sequence. Interestingly, Cys162, one of the 
three Cys residues, is highly exposed at the protein surface (26). Thus, this unique modification 


































Figure 3.2. ESI-MS spectra of p38α and modified p38α by compound 2. (a) Unphosphorylated 
p38α was incubated for 12 h at 25 °C; (b) Unphosphorylated p38α incubated with N-





Figure 3.3. MALDI-MS spectra of p38α treated with N-alkynylimidazole 2 and untreated p38α 





























Figure 3.5. ESI-MS spectrum of unphosphorylated p38α incubated with iodoacetamide for 12 h 












3.3. DETERMINATION OF KINETIC PARAMETERS OF MODIFIED P38 BY COMPOUND 2 
We showed that compound 2 covalently modifies Cys119 in the D-recruitment site of 
p38α. To investigate whether this modification would affect p38α kinetic properties, we 
performed in vitro kinase assays to evaluate the ability of the modified p38α to phosphorylate 
two different protein substrates, activating transcription 2 (ATF2) and mitogen-activated protein 
kinase-activated protein kinase 2 (MK2), and one peptide substrate (Ste7 peptide).  
 
Substrate p38α Modified p38α 
 Km (µM) kcat (sec
-1
) Km (µM) kcat (sec
-1
) 
ATF2 2.22 ± 0.64 1.5 ± 0.06 3.74 ± 0.74 1.075 ± 0.02 
MK2 6.65 ± 2 1.3 ± 0.12 1.12 ± 0.21 0.563 ± 0.02 
Ste7-peptide 
Substrate 
47.82 ± 22.05 5.4 ± 1.11 28.77 ± 8.71 3.4 ± 0.37 
Table 3.1. Kinetic constants for phosphorylation of different substrates by p38α and modified 
p38α. 
Table 3.1 shows the kinetic parameters Km and kcat obtained by measuring the initial 
velocity data at different concentrations of each tested substrate and fixed concentration of ATP. 
Modification of p38α by compound 2 at Cys119 affected both the binding affinity of p38α to 
ATF2 and the ability of p38α to phosphorylate ATF2, as Km increased from 2.22 to 3.74 µM and 
kcat decreased from 1.5 to 1 s
-1
 (Figure 3.7). The specificity constant kcat/Km is decreased by 2-3 




), suggesting that modification at Cys119 by compound 2 might 
affect the docking of ATF2 to p38α. 
In contrast, modification of Cys119 by compound 2 showed an increase in the specificity 










 for both p38α and modified p38α) (Figure 3.9). Ste7 peptide substrate 
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(FQRKTLQRRLKGLNLNL-AHX-TGPLSPGPF, where AHX is a linker) has a specific D-site 
to the MAP kinases (described in Lee et al, Submitted to Biochemistry). This suggests that MK2 

























Figure 3.7. Analysis of the kinase activity of the modified p38α with ATF2 substrate. 
Phosphorylation of the protein substrate ATF2 (2.5-40 M) by 8 nM activated p38α (red solid 
line) or 8 nM activated modified p38α by compound 2 (blue dashed line) in the presence of 0.5 











Figure 3.8. Analysis of the kinase activity of the modified p38α with MK2 substrate. 
Phosphorylation of the protein substrate MK2 (0.5-40 M) by 10 nM activated p38α (red solid 
line) or 10 nM activated modified p38α with compound 2 (blue dashed line) in the presence of 









   
Figure 3.9. Analysis of the kinase activity of the modified p38α with Ste7 peptide substrate. 
Phosphorylation of the Ste7-peptide substrate (5-100 M) by 10 nM activated p38α (red solid 
line) or 10 nM activated modified p38α with compound 2 (blue dashed line) in the presence of 







3.4. DESIGN AND SYNTHESIS OF COVALENT P38DOCKING SITE PROBE  
We propose that the reaction mechanism involves nucleophilic addition of the cysteine thiol to 
the N-ethynyl group. To model the thioenol ether formation in the protein modification, N-
alkynylimidazole derivatives 3, 4, 5 were treated with thiophenol in THF at room temperature 
(Scheme 3.1). Based on NOESY NMR, the isolated thiol enol ether adduction products 6, 7, 8 









3   R = H
4   R = F
5   R = Br
1.1eq PhSH
THF, rt. overnight
6   R = H
7   R = F
8   R = Br  
Scheme 3.1. Synthesis of (Z)-thioenol ether. 
To the best of our knowledge, no small molecule class has been identified to selectively 
modify Cys119 residue in p38α. Such compounds would be useful in serving as docking site 
probes for biochemical and cellular studies. Recently, we reported a mechanism for cytotoxicity 
involving the selective thiol addition to the N-ethynyl group of certain 1,2-dialkynylimidazoles 
(Scheme 3.2) (30). Based on the unexpected electrophilic nature of the N-ethynyl group, 
dialkynylimidazole 11 was developed as a covalent p38α docking site probe. After the addition 
of docking site cysteine thiol to the N-ethynyl group, the second alkyne introduced at the 2 
position of the imidazole is available for further functionalization, such as azide-alkyne “Click” 
chemistry. Dialkynylimidazole 11 was synthesized using our previously published synthetic 
route (31). Iodination of 9 gave 1-alkynyl-2-iodo-4-(4-fluorphenyl)-imidazole 10, which was 
then coupled to triisopropylsilyl acetylene under standard Sonogashira coupling condition, 
84 
followed by desilylation (Scheme 3.3). As shown in Figure 3.10, after incubation of 11 with 
p38α at 25 °C, we carried out a Cu(I) catalyzed 1,3-dipolar cycloaddition with an azide-labeled 
fluorescent dye. Then the reaction mixture was subjected to denaturing gel electrophoresis and 


















Scheme 3.2. Synthesis of (Z)-thioenol ether. 
 
 
















Scheme 3.3. Synthesis of dialkynylimidazole. Reagents and conditions: (a) (i) n-BuLi; (ii) I2, 
THF, -78 °C (90 %); (b) (i) TMSCCH, Pd(PPh3)4, CuI, Et3N; (ii) TBAF, THF, -78 °C (82 %). 
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3.5. IN VITRO AND IN CELL LABELING OF P38  
p38α (5 µM) was incubated with 11 (100 µM) in 50 mM HEPES, pH 7.5, 1 mM EGTA, 
2 mM DTT, 10 mM MgCl2 for 16 h at 25°C. After incubation, the Cu (I) catalyzed 1,3 dipolar 
cycloaddition reaction was carried out as follows: 25 g p38 in 50 mM phosphate buffer (50  l 
total volume) was incubated with 0.5 l CuSO4 (50 mM), 0.5 l tris(2-carboxyethyl)phosphine 
(TCEP, 50 mM) and 1.65 l tris[(1-benzyl-1H-1,2,3-triaol-4-yl)methyl]amine (TBTA, 1.5 mM) 
at 25 °C for 16 h. Then the “Click” reaction was quenched with addition of 2x SDS loading 
buffer and heat inactivated at 95 °C for 10 min. The samples were analyzed by 10 % SDS 
PAGE. The gel was scanned and the data were analyzed. As shown in Figure 3.8, a strong 
fluorescent band with a loading of 0.4 µg of the protein was detected in Lane 3. As two controls, 
p38α alone or treatment of p38α with the “Click” reaction reagents (Alexa594-azide, CuSO4, 
TBTA and TCEP) showed no fluorescent bands with a loading of 2 µg of the protein in Lanes 1 
and 2 (Figure 3.11). The approximate detection limit for the adducted p38α was determined to be 
1 ng.  
In addition, we also studied the kinetics of the “Click” chemistry reaction. After 
incubation of p38α with 11 for 16 h at 25 °C, the “Click” chemistry was carried out: 5 g p38 
in 50 mM phosphate buffer (50 l total volume) was incubated with 0.5 l CuSO4 (50 mM), 0.5 
l tris(2-carboxyethyl)phosphine (TCEP, 50 mM) and 1.65 l tris[(1-benzyl-1H-1,2,3-triaol-4-
yl)methyl]amine (TBTA, 1.5 mM), 0.5 l GSH (0.5 mM) at 25 °C. Aliquots of the solution were 
then removed at various time points from 0.5 h to 24 h (Figure 3.12), followed by SDS-PAGE 
analysis. The gel was scanned and the data was fit to P = Pmax(1-e
-kobst),  and the kobs and the half-
life were estimated to be 0.117 h
-1







Figure 3.11. In vitro labeling of p38α. p38α was incubated with 11 followed by “Click” 
chemistry. Left gel: As two controls, p38α was either incubated alone or with the “Click” 
chemistry reagents: Alexa594-azide, CuSO4, TBTA and TCEP. Right gel: SDS-PAGE gel was 
stained with Commassie Blue.   
 
 
Figure 3.12. Time-course study of the “Click” chemistry reaction. p38α was incubated with 11 
for 16 h at °C. Aliquots were removed at various time points during the “Click” chemistry. 
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Figure 3.13. Determination of the half-life of the “Click” chemistry. 
We next investigated the ability of this probe to detect p38α in cells. By transient 
transfection, p38α bearing an N-terminal FlAG-tag was expressed in HEK 293T cells. We 
treated the cells with 11 in DMSO (final concentrations: 1 µM, 5 µM, 50 µM) and incubated the 
cells at 37 °C for 4 h. Subsequently, the cells were pooled, washed with cold PBS pH 7.4, and 
harvested. Cell pellets were lysed in lysis buffer containing protease inhibitors. After lysis, the 
cell lysate were centrifuged. Supernatant was then collected and incubated with ANTI-FLAG 
M2 affinity gel overnight at 4 °C. The resin was centrifuged and washed with TBS three times. 
FlAG-p38 was eluted by a competition with FLAG peptide. The resulting supernatant was 
incubated with Alexa594-azide and catalysts for the cycloaddition reaction, followed by SDS-
PAGE analysis. Addition of various concentrations of 11 to the cells resulted in an increase in 
fluorescence in a dose-dependent manner as shown in Lanes 2, 3 and 4. As a negative control, 
treatment of the cells with DMSO did not show fluorescence band. As a positive control, 
treatment of the cell lysate with 11 in vitro followed by immunoprecipitation and “Click” 





Figure 3.14. In cell labeling of p38α by 11. After transient transfection of p38α, HEK293T cells 
were treated with 1 M, 5 M, 50 M 11, and 0.05 % DMSO followed by immunoprecipitation 







3.6. SELECTIVITY OF 11 TOWARDS ENDOGENOUS P38  
We have demonstrated that our probe can fluorescently label recombinant p38in vitro 
and overexpressed p38in cells. To test the reactivity of 11 with p38we next added 
recombinant p38to THP-1 cell lysate (THP-1 cell lysate: p38 1 by mass), and carried 
out an incubation with compound 11 for 16 h at 25 °C followed by the “Click” chemistry. As a 
result, our compound 11 showed selectivity towards p38as shown in Lane 2. As a negative 
control, THP-1 cell lysate was incubated with compound 11 followed by the “Click” chemistry 
(Lane 1). As a positive control, p38was incubated with 11 followed by the “Click” chemistry 
(Lane 3) (Figure 3.15). 
In order to test the selectivity of 11 towards endogenous p38, we incubated THP-1 (100 
g) cell lysate with compound 11 (0.5 mM) for 24 h at 25 °C followed by the “Click” chemistry 
(Lane 4). As negative controls, THP-1 cell lysate was incubated alone (Lane 1); THP-1 cell 
lysate was incubated with compound 11 only without the following “Click” chemistry (Lane 2); 
THP-1 cell lysate was incubated with the “Click” reaction reagents (Alexa594-azide, CuSO4, 
TBTA and TCEP) (Lane 3). No fluorescent bands were detected in these three lanes. As a 
positive control, p38was incubated with 11 followed by the “Click” chemistry, resulting in a 
fluorescent band (Lane 5). As shown in lane 4, multiple proteins were labeled by 11 in the cell 









Figure 3.15. Selectivity study of 11 in THP-1 cell lysate with recombinant p38THP-1 (40 g) 
cell lysate or cell lysate/p38 mixture (40 g) was incubated with 11 (0.2 mM) for 16 h at 25 °C 







                
 
Figure 3.16. Selectivity study of 11 in THP-1 cell lysate. THP-1 (100 g) cell lysate was 









3.7. MKK3 D-SITE PEPTIDE CAN DIMINISH THE INTERACTION BETWEEN 11 AND P38 
Recently, the selectivity of the MKK3 D-site peptide among MAPKs has been evaluated:  
the results indicate that the peptide is a remarkably potent inhibitor of p38α (IC50 <10 nM), and 
this peptide does not inhibit JNK1 or JNK2 (22). To ascertain if our probe 11 targets the DRS, 
the following study was carried out to determine whether MKK3 peptide could affect the 
interaction between 11 and the DRS. We pre-incubated p38 with either MKK3 peptide or 
compound 2 for 16 h at 25 °C followed by incubation with 11 for an additional 16 h and “Click” 
chemistry. In comparison to the control (incubation of p38with 11 alone), a reduction in 
fluorescence intensity (23 normalized %) was detected in Lane 2 (Figure 3.17). This suggests the 
MKK3 peptide is able to diminish the interaction between 11 and the DRS in p38.  In Lane 3, 
44 % relative fluorescence was detected. It is possible that Cys119 in p38 did not completely 
react with compound 2 during the pre-incubation. In addition, 11 and the MKK3 peptide were 
added simultaneously to p38α followed by “Click” chemistry. As a control, we used Ste7 
peptide, which has a lower affinity for p38α (described in Lee et al, Submitted to Biochemistry).  
Interestingly, our data showed that the MKK3 peptide competes against 11 for binding to p38α, 
resulting in 84 % inhibition of adduct in lane 1 (Figure 3.18). Additionally, 28 % inhibition of 
adduct was detected when p38α was incubated with Ste7 peptide and 11 in Lane 2 (Figure 3.18). 
Altogether, the above results demonstrate that 11 targets the DRS and the MKK3 peptide can 









Figure 3.17. Competition assay between MKK3 peptide and compound 11. MKK 3 peptide 
(Lane 2) or 2 (Lane 3) was pre-incubated with p38 for 16 h at 25 °C followed by addition of 11 









Figure 3.18. Competition assay between MKK3 peptide and compound 11.  MKK3 peptide 
(Lane 1) or Ste7 peptide (Lane 2) was incubated with p38 and 11 together for 16 h at 25 °C 











Figure 3.19. MKK3 peptide and Ste7 peptide bind to the D-recruitment site (DRS). 1,2-








3.8. COMPETITION ASSAY BETWEEN 11 AND TEST COMPOUNDS  
Encouraged by our previous results, we carried out the subsequent studies to test the 
possibility of further developing this fluorescent-based assay for screening new DRS inhibitors. 
We first carried out a competition assay by adding N-alkynylimidazole analogs 3, 4, 5, 12 (100 
M each) along with 11 (100 M) to p38α (5 M). The incubation was performed at 25 °C for 
16 h followed by the “Click” chemistry. Clearly, analog 12 in Lane 5 competes with 11 for 
binding to Cys119 in the docking site of p38α, as the fluorescence intensity is much reduced 
compared to the control in Lane 1. Analog 11 is a water soluble N-alkynylimidazole whereas 
other analogs are hydrophobic. Therefore, we suspect that hydrophilicity may play a role in the 




Figure 3.20. Competition assay between 11 and N-alkynylimidazole analogs. p38α was 




In addition to N-alkynylimidazole analogs, we also carried out a competition assay 
between caffeic acid phenethyl ester (CAPE) and 11. The structure of CAPE is shown below. 
Similarly, the competition experiment was performed by incubating p38α (5 M) with CAPE 
(100 M) and 11 (100 M) at 25 °C for 16 h followed by the “Click” chemistry (Lane 2). As a 
positive control, p38was incubated with 11 followed by the “Click” chemistry (Lane 1). 
Interestingly, CAPE reduces the interaction between 11 and p38α. It is possible that the 
mechanism involves nucleophilic addition of the cysteine thiol to the Michael receptor of CAPE. 
Based on the above competition studies, we can potentially use this fluorescence based assay to 
identify small molecules that react more quickly than 11 with Cys119. Additionally, further 
mechanistic study of CAPE on p38α remains to be investigated.  
 
 
Figure 3.21. Competition assay between 11 and CAPE. p38α was incubated with 11 and CAPE 
for 16 h at 25 °C followed by “Click” chemistry.  
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3.9. Determination of the half-life of p38adduction by 11 
In order to optimize the incubation time for this fluorescence-based assay, we first 
determined the half-life for this covalent adduction. Compound 11 (25 M) was incubated with 
p38α (5 M), and aliquots were removed at various time points followed by “Click” chemistry 
and SDS-PAGE analysis. The fluorescent gel was scanned and quantified using Image J 
software. The data was fit to P = Pmax(1-e
-kobst), and the kobs and the half-life of this covalent 
adduction was estimated to be 0.11 h
-1
 and 6 h, respectively, following pseudo first-order 
kinetics. Assuming that the pseudo-first order rate constant for the adduct formation is linearly 
dependent on the excess concentration of compound 11, and the observed increase in the 
fluorescence level after the “Click” chemistry reaction is a direct result of  compound 11 
irreversibly binding to p38α (koff = zero). We can extract a second-order rate constant for 








Figure 3.22. Determination of the half-life of the covalent adduction reaction. Compound 11 was 
incubated with p38α, and aliquots were removed as different time points followed by “Click” 
chemistry. 
time (h)

















3.10. CONCLUSION AND FUTURE DIRECTION 
The research discussed here provides a potential alternative for developing new and 
selective inhibitors that target the substrate binding site. Here we present a novel class of small 
molecules as docking site probes for p38α. We showed that N-alkynylimidazole 2 selectively 
labels Cys119 in the D-recruitment site of p38α. We also demonstrated that 1,2-
dialkynylimidazole 11 can fluorescently label p38α in vitro and in cells, and the interaction 
between 11 and p38α can be diminished by the p38α-cognate MKK3 peptide. However, several 
limitations also arise from this fluorescence-based assay. For instance, our probe is not selective 
towards endogenous p38α. Therefore, further development of a kinase/substrate specific probe is 
required. Moreover, the reaction time of the covalent chemistry is long. It would not be ideal for 
a high-throughput screening assay. Furthermore, this fluorescence-based approach must be 
optimized so that the wash steps would be minimized for a screening assay.  
 To design a more kinase/substrate specific probe for p38α, one way is to couple a 
dialkynylimidazole analog with a highly selective D-site peptide (i.e. MKK3 peptide) (Figure 
3.23). The D-site peptide will guide the probe to the docking site of p38α, where the covalent 
modification occurs. A high-throughput screening assay can be developed using this covalent 
peptide. This approach not only allows us to discover selective D-site inhibitors but also has an 
advantage of ruling out false hits that target the ATP binding pocket. Additionally, we can apply 
the same strategy to other kinases that contains cysteine residues in the unique binding site. For 
example, both ERK2 and JNK have one cysteine in the D-recruitment site, Cys159 and Cys163, 
respectively (29).  













Figure 3.23. Dialkynylimidazole-coupled MKK3 peptide.  
 
In the meantime, a structural optimization of compound 11 can be carried out. We 
showed that compound 12 is able to compete with 11 for binding to Cys119. Further 
functionalization at the 4 or 5 position of the imidazole is required to identify a better analog that 
quickly reacts with Cys119. Then we can perform competition studies described previously in 
the chapter to evaluate the reactivity of dialkynylimidazole candidates.  
In general, fluorescence assays that do not require wash steps are much preferred. One 
way to minimize wash steps is to label p38α with a second fluorophore near Cys119. Instead of 
measuring the fluorescence of Alexa 594 in our current fluorescence-based assay, we can detect 
a FRET signal between the new fluorophore (near Cys119) and the fluorophore (from “Click” 
chemistry). For example, we can use the tetracysteine-biarsenical system to fluorescently label 
p38α. The biarsenical labeling reagents FlAsh-EDT2 and ReAsH-EDT2 bind to recombinant 
p38α containing the tetracysteine (TC) motif Cys-Cys-Pro-Gly-Cys-Cys bind to. Upon binding, 
the labeling reagents become fluorescent. By this way, we can avoid the step for washing out 
free fluorophore after the “Click” chemistry step (32). Overall, this approach can shorten the 







3.11. EXPERIMENTAL SECTION 
General: All reactions were carried out under argon in oven-dried glassware with magnetic 
stirring. Unless otherwise noted, all materials were obtained from commercial suppliers and were 
used without further purification. CuI was purified by recrystallization and Cs2CO3 was heated 
several times with a heat gun in the reaction flask under vacuum prior to use. THF, 1,4-dioxane 
were distilled from sodium/benzophenone prior to use. Unless otherwise noted, organic extracts 
were dried with Na2SO4, filtered through a fritted glass funnel, and concentrated with a rotary 
evaporator (20–30 mmHg). Rf values are reported for analytical thin-layer chromatography 
(TLC) performed on 0.25 mm silica gel 60-F plates with UV light or KMnO4 visualization. Flash 
chromatography was performed with silica gel (230–400 mesh) using the mobile phase 





NMR spectra were determined in CDCl3 on a spectrometer operating at 400 and 100 MHz, 
respectively, and are reported in ppm using solvent as internal standard (7.26 ppm for 
1
H and 
77.0 ppm for 
13
C). All mass spectra were obtained in the positive mode by chemical ionization 

















To 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(2-triisopropylsilanyl)-1H-imidazole (5 mg, 0.01 mmol) 
in THF (2 ml) at -78 °C was added TBAF (0.015 ml of 1 M solution in THF, 0.012 mmol), and 
the reaction mixture was stirred at -78 °C until completion. The reaction mixture was quenched 
with water (2 ml) and extracted with CH2Cl2 three times. The organic layers were combined, 
dried over Na2SO4 and the solvent was evaporated under reduce pressure. The residue was 
purified by flash chromatography (0-50 % EtOAc/hexane) to afford 4-(4-fluorophenyl)-5-(4-
pyridyl)-1-ethynyl-1H-imidazole 2 (3 mg, yield 96 %) as a light yellow solid: mp = 123.0-124.0 
ºC;
 1
H NMR (CDCl3) δ: 8.69 (br, 2H), 7.94 (s, 1H), 7.48-7.39 (m, 2H), 7.40-7.39 (m, 2H), 7.02-
6.98 (m, 2H); MS m/z: HRMS (CI) calcd for C16H11N3FN3 (M
+

















To a solution of 4-(4-fluorophenyl)-2-iodo-1-((triisopropylsilyl)ethynyl)-1H-imidazole  (145 mg, 
0.30 mmol) in Et3N (4 ml) was added ethynyltrimethylsilane (0.05 ml, 0.36 mmol), Pd(PPh3)4 
(17 mg, 0.015 mmol) and CuI (5.7 mg, 0.03 mmol). The reaction mixture was stirred at room 
temperature until the starting material was completely consumed. The reaction mixture was 
filtered. The filtrate was evaporated, and the residue was purified by flash chromatography (0-2 
% EtOAc/hexane) to afford 4-(4-fluorophenyl)-1-(2-triisopropylsilylethynyl)-2-(2-
trimethylsilylethynyl)-1H-imidazole (Quantitative yield). To this material (18 mg, 0.045 mmol) 
in THF (1.4 ml) at -78 °C was added TBAF (0.09 ml of 1 M solution in THF, 0.09 mmol), and 
the reaction mixture was stirred at -78 °C until completion. The reaction mixture was quenched 
with water (2 ml) and extracted with CH2Cl2 three times. The organic layers were combined, 
dried over Na2SO4 and the solvent was evaporated under reduce pressure. The residue was 
purified by flash chromatography (0-20 % EtOAc/hexane) to afford 4-(phenyl)-1-(ethynyl)-2-





(400 MHz, CDCl3) δ 7.75-7.72 (2H, m), 7.34 (1H, s), 7.10-7.06 (2H, m), 3.44 (1H, s), 3.24 (1H, 
s); 
13
C NMR (100 MHz, CDCl3) δ 162.6 (d, J = 246 Hz), 141.2, 134.4, 128.1 (d, J = 2.9 Hz), 
127.1 (2C, d, J = 8.2 Hz), 117.2, 115.7 (2C, d, J = 21.6 Hz), 82.7, 71.5, 70.4, 62.3; MS m/z:   
HRMS (CI) calc for C13 H8 N2 F (M+H
+










 (Z)-4-phenyl-1-(2-(phenylthio)vinyl)-1H-imidazole (6):  
To a solution of 4-phenyl-1-ethynyl-1H-imidazole (15 mg, 0.09 mmol) in THF (2 ml) was added 
thiophenol (0.1mmol, 0.01 ml). The reaction mixture was stirred at room temperature overnight. 
The reaction mixture was concentrated, and the residue was purified by flash chromatography 




H NMR (400 MHz, CDCl3) δ 7.77-7.76 (2H, m), 7.75 (1H, s), 7.67 (1H, s), 7.40- 3.38 (2H, m), 
7.35-7.26 (4H, m), 7.24-7.19 (2H, m), 6.81 (1H, d, J = 8.4 Hz), 6.04 (1H, d, J = 8.4 Hz); 
13
C 
NMR (100 MHz, CDCl3) δ 142.4, 137.7, 134.2, 133.5, 130.1 (2C), 129.4 (2C), 128.6 (2C), 
127.8, 127.1, 125.0 (2C), 121.2, 115.1, 114.1; MS m/z: HRMS (CI) calc for C17H15N2S (M
+
) 




















(Z)-4-(4-fluorophenyl)-1-(2-(phenylthio)vinyl)-1H-imidazole (7):  





H NMR (400 MHz, CDCl3) δ 7.82 (1H, d, J = 1.2 Hz), 7.80-7.77 (2H, m), 
7.67 (1H, d, J = 1.2 Hz), 7.46-7.43 (2H, m), 7.39-7.30 (3H, m), 7.11-7.06 (2H, m), 6.87 (1H, d, J 
= 8.4 Hz), 6.11 (1H, d, J = 8.4 Hz); 
13
C NMR (100 MHz, CDCl3) δ 162.1 (d, J = 244.1 Hz), 
141.5, 137.7. 134.1, 130.0 (2C), 129.7 (d, J = 3.0 Hz), 129.4 (2C), 127.8, 126.6 (2C, d, J = 8.1 
Hz), 121.1, 115.6, 115.3 (2C, d, J = 12.6 Hz), 113.7; MS m/z: HRMS (CI) calc for C17H14N2FS 
(M
+



















(Z)-4-(4-bromophenyl)-1-(2-(phenylthio)vinyl)-1H-imidazole (8):  





H NMR (400 MHz, CDCl3) δ 7.83, 7.72-7.68 (3H, m), 7.53-7.50 (2H, m), 
7.47-7.44 (2H, m), 7.40-7.32 (3H, m); 
13
C NMR (100 MHz, CDCl3) δ 141.4, 137.8, 134.1, 132.5, 
131.7 (2C), 130.1 (2C), 129.4 (2C), 127.8, 126.6 (2C), 121.0, 120.8, 115.6, 114.3 ; MS m/z:    
HRMS (CI) calc for C17H14N2Br S (M
+




















1-ethynyl-4-(4-bromophenyl)-1H-imidazole (5):  
A reaction flask under argon was charged with Cs2CO3 (3.25 g, 10 mmol), CuI (60 mg, 0.25 
mmol), and 4-bromophenyl-imidazole (1.1g, 5 mmol) and backfilled with argon. Dry 1,4-
dioxane (10 mL) was added followed by bromotriisopropylacetylene (0.237 mL, 10 mmol), 2-
acetylcyclohexanone (0.125 mL, 1 mmol). The mixture was heated to 50 °C in an oil bath for 14 
h and then heated to reflux for 4 h. The reaction mixture was cooled to room temperature, 
quenched with 10 mL of a saturated NH4Cl solution, and extracted with CH2Cl2 (3× 20 mL). The 
combined organic layers were evaporated and (flash chromatography; 0–5% EtOAc/hexane), 55 
mg of 4-(4-bromophenyl)-1-((triisopropylsilyl)ethynyl)-1H-imidazole (67 % yield) was 




H NMR (400 MHz, CDCl3) δ 7.77 (1H, d, J = 
1.2 Hz), 7.65-7.63 (2H, m), 7.52-7.50 (2H, m), 7.39 (1H, d, J = 1.2 Hz), 1.14-1.12 (21H, m); 
13
C 
NMR (100 MHz, CDCl3) δ 140.6, 140.5, 131.8 (2C), 131.7, 126.7 (2C), 121.3, 117.1, 91.4, 70.5, 
18.5 (6C), 11.1 (3C); MS m/z: HRMS (CI) calc for C20H27N2SiBr (M
+
) 402.1127, found 
402.1129. To this material (59 mg, 0.15 mmol) in THF (3.2 ml) at -78 °C was added TBAF (0.15 
ml of 1 M solution in THF, 0.15 mmol), and the reaction mixture was stirred at -78 °C until 
completion. The reaction mixture was quenched with water (4 ml) and extracted with CH2Cl2 
three times. The organic layers were combined, dried over Na2SO4 and the solvent was 
evaporated under reduce pressure. The residue was purified by flash chromatography (0-20 % 
EtOAc/hexane) to afford 34 mg 5 as an off-white solid (95 % yield): 
1
H NMR (400 MHz, 
109 
CDCl3) δ 7.79 (1H, s), 7.63-7.60 (2H, m), 7.51-7.48 (2H, m), 7.36 (1H, s); 
13
C NMR (100 MHz, 
CDCl3) δ 140.8, 140.5, 131.8 (2C), 131.4, 126.8 (2C), 121.5, 116.8, 71.3, 59.7; MS m/z: HRMS 
(CI) calc for C11 H7 N2 Br (M
+













































Following the same procedure described: 4 was obtained as a beige solid (79 % yield):  
1
H NMR 
(400 MHz, CDCl3) δ 7.79 (1H, s), 7.75-7.70 (2H, m), 7.33 (1H, s), 7.11-7.05 (2H, m); 
13
C NMR 
(100 MHz, CDCl3) δ162.4 (d, J = 245.5 Hz), 141.1, 140.4 (2C), 128.71 (d, J = 3 Hz), 127.0, 
126.9 (2C, d, J = 8.2 Hz), 116.2 (2C), 115.6 (2C, d, J = 21.6 Hz), 71.4, 59.5; MS m/z:  HRMS 
(CI) calc for C11 H7 N2 F (M+H
+























Identification of site modification on p38 by N-alkynylimidazole 2: 
The reaction consists of 5 µM p38, 100 µM 2 in 50 mM HEPES, pH 7.5, 1 mM EGTA, 2 mM 
DTT, 10 mM MgCl2. After 12 h incubation at 25 °C , the reaction mixture was dialyzed in 1 
Liter of 25 mM HEPES, pH 7.5, 1 mM DTT, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 10 % 
(v/v) glycerol. After 12 h dialysis at 4 °C, the protein was concentrated and subjected to ESI 
mass spectrometry.  
The N-alkynylimidazole 2 adducted p38 was digested with chymotrypsin (chymotrypsin: 
peptide = 1: 20 w/w) in 100 mM Tris-HCl containing 20 mM CaCl2, pH 7.8 at 30 °C for 12 h. 
The digested sample was subjected to MALDI mass spectrometry.  
 
In vitro labeling of p38by 11: 
The reaction consists of 5 µM p38, 100 µM 2 in 50 mM HEPES, pH 7.5, 1 mM EGTA, 2 mM 
DTT, 10 mM MgCl2. After 16 h incubation at 25 °C, the Cu (I) catalyzed 1,3 dipolar 
cycloaddition reaction was carried out as follows: 25 g p38 in 50 mM Phosphate Buffer was 
incubated with 0.5 l CuSO4 (50 mM), 0.5 l tris(2-carboxyethyl)phosphine (TCEP, 50 mM) 
and 1.65 l tris[(1-benzyl-1H-1,2,3-triaol-4-yl)methyl]amine (TBTA, 1.5 mM) at 25 °C for 16 h. 
Then the “click” reaction was quenched with addition of 2x SDS loading buffer and heat 
inactivated at 95 °C for 10 min. The samples were analyzed by 10 % SDS PAGE. The gel was 








In cell labeling of p38:  
HEK 293T cells (5 x 10
5
 cells) were seeded on a 6 well polystyrene plate in DMEM 
supplemented with 10 % FBS (Invitrogen) and 1 % L-glutamine. Cells were grown to 90-95 % 
confluency in an atmosphere of 5 % CO2, pCDNA3 Flag p38 (Addgene) was transfected into 
HEK 293T cells using polyethyleneimine (PEI). After 48 h incubation, old medium was 
removed. Compound 11 was added in new growth medium. The cells were incubated at 37 °C 
for 4 h. After the treatment, cells were pooled, spinned down at 1200 rpm and washed twice with 
cold PBS pH 7.4. Cell pellets were lysed in lysis buffer containing protease inhibitors (Thermo 
Scientific). The resulting solution was incubated at 4 °C for 30 min. The cell lysates were 
centrifuged at 14,000 rpm at 4 °C for 10 min. Supernatant was collected and incubated with 
ANTI-FLAG M2 affinity gel overnight at 4 °C. The resin was centrifuged and washed with TBS 
three times. Flag-p38 was eluted by a competition with FLAG peptide. The Cu (I) catalyzed 1,3 













p38 MAPK assays were conducted at 27 °C in assay buffer A1 (20 mm Hepes, 2 mm 




 bovine serum albumin, 
pH 7.6) containing 8–10 nm activated p38 MAPK and 10 mm MgCl2 in a final volume of 100 
L. The concentrations of substrates ranged as follows: ATF2 (1-115) or MK2 (Δ40 MK2) or 
Ste7 (0.5–100 M), ATP (0.5 mM, 1000 c.p.m.pmol
-1
). The reaction mixture was incubated for 5 
min before the addition of ATP. Aliquots (10 L) were taken at set time points and applied to a 2 
x 2 cm P81 cellulose papers, which were allowed to air-dry, washed with 50 mm phosphoric acid 
(5 x 10 min), then in acetone (1 x 10 min) and dried. The incorporation of radioactivity was 
determined by counting in 1.5 mL CytoScint on a Packard 1500 scintillation counter at a ζ-value 
of 2. Protein concentrations were determined at 280 nm using the following molar extinction 




 (p38 MAPK), ATP concentration was determined at 259 nm 
using 52 501 M
-1.
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Biological evaluation of 1,2-dialkynylimidazole as anti-cancer agents: aza-
Bergman rearrangement do not predict cytotoxicity 
 
4.1. INTRODUCTION 
The extreme cancer cell cytotoxicity of natural enediyne compounds such as 
calcheamincin  (1), esperamicin A1 (2) or dynemicin A (3) involves DNA cleavage via 
diradical intermediates arising from cyclization of enediyne core (4). In order to address the 
selectivity issues associated with natural products, a wide variety of enediyne analogs have been 
prepared and examined for DNA cleavage and cancer cell cytotoxicity activities (5-8). In this 
respect, computational chemistry has substantially aided in the design of enediynes that undergo 
diradical-generating Bergman cyclization under physiological conditions (9-13). 
Recently, several enediynes have been described that do not undergo Bergman 
cyclization under physiological conditions, but which still display interesting cancer cell 
cytotoxicity (14-16). These enediynes induce G2/M cell cycle arrest by targeting microtubule 
formation (14), although other targets such as topoisomerase I and MAPK pathways have also 
been proposed (15, 16).   
1,2-Dialkynylimidazoles have been investigated as a class of aza-enediynes (Figure 1) 
(17-20), which are considered potential DNA-cleaving anticancer agents with improved 
selectivity in comparison with the enediynes. We reported the novel thermolysis and 
rearrangement of 1,2-dialkynylimidazoles as described in Chapter 1. Here we address the unique 
and potent cancer cell cytotoxicity of the 1,2-dialkynylimidazole 1a (Figure 4.1).  In order to 
better understand the structural basis and role of the thermal generation of diradical and/or 
carbene intermediates in the cytotoxicity demonstrated by 1a, we have prepared a series of 
dialkynylimidazoles and related imidazoles and determined their cytotoxicity against A549 
human non-small cell lung cancer cells. The aza-Bergman cyclization kinetics of selected 
118 
dialkynylimidazoles was also studied experimentally and by DFT calculations. Interestingly, 
although some of these dialkynylimidazoels are very cytotoxic to A549 cells, the degree of 
cytotoxicity is unrelated to the kinetics of aza-Bergman cyclization. Furthermore, we find 
evidence that the 1-ethynylimidazole moiety contributes to the cytotoxicity of these compounds, 


















4.2. SYNTHESIS OF 1,2-DIALKYNYLIMIDAZOLES AND N-ALKYNYLIMIDAZOLES  
The 1,2-dialkynylimidazoles 1a-p were prepared with Dr. Christophe Laroche from 
previously reported 1-alkynyl-2-idoimiiidazoles 4a-g, which were coupled to a variety of 
terminal alkynes under standard Sonogashira coupling conditions followed by silyl deprotection 


























































































































































Table 4.1. Synthesis of Dialkynylimidazoles 1a-p. 
a
An optional deprotection of silyl groups was carried out, except in the case of reactions of 4c. 
b
In 4a R = TIPS; see ref 27. 
c






In 4c R = CH2OTBDMS; 
see ref 20. 
f
In 4e,g, R = TIPS; see ref 20. 
g
see ref 19. 
h
see ref 18.   
 
Related alkynylimidazoles 5a and 5b were prepared as previously described (21). 
Deprotection of the silylalkynylimidazole 6a afforded the ethynylimidazole 6b. The 1-
methylimidazole 7 was prepared from 1-tert-butoxycarbonyl-2-iodoimidazole by Sonogashira 
coupling, deprotection, and methylation (Scheme 4.1). Treating the dialkynylimidazole 1a with 
thiophenol in THF at room temperature for 5 days afforded the addition product 8 as a single 
diastereomer that was assigned the (Z)-configuration based on 
1
H NMR coupling constants (8.4 



















Pd(PPh3)4, CuI, Et3N, 50 C
2. TFA, -5 C



















5a: R = H
5b: R= CH2CH2Ph
6a: R = TIPS
6b: R = H
7
1a 8  
 








4.3. APOPTOSIS ASSAY OF 1,2-DIALKYNYLIMIDAZOLE 
The cytotoxicity (22) of 1,2-dialkynylimidazole 1a has been evaluated by the National 
Cancer Institute against 60 cancer cell lines. Compound 1a showed inhibition activity against a 




 M and a mean GI50 of 3 M. Although a 
COMPARE analysis (23) showed that these is no similarities between 1a and standard anticancer 
drugs (correlation co-efficient < 0.5), within the set of compounds selected by the NCI for in vivo 
testing, the activity of 1a correlated most strongly (P = 0.727 to 0.602) to a series of quinoxaline 
1,4-dioxides. These specific quinoxaline 1,4-dioxides have been shown to produce hydroxyl 
radicals and cleave DNA under aerobic conditions through redox cycling involving the 
NADPH/cytochrome P450 reductase system (24). Under anaerobic conditions, the one-electron 
reduction of quinoxaline 1,4-dioxides is accompanied by radical fragmentation to afford 
stoichiometric hydroxyl radicals (25). 
In order to gain more insight into the mechanism of action of the dialkynylimidazole 1a, 
studies were conducted in the human non-small cell lung cancer cell line A549 (26), which is a 
well characterized standard human alveolar epithelial cell line. A549 cells were incubated with 
various concentration of 1a and the extent of apoptosis was determined by flow cytometry 
(Figure 4.2).  
After treating A549 cells with 5 M of compound 1a for 24 h, the proportion of apoptotic 
cells increased to 63 %, 25-times higher than the proportion of apoptotic cells in the absence of 
1a. Even at concentrations as low as 1.25 M, compound 1a caused a significant increase in the 







The spectrum of anticancer activity of 3 analyzed by COMPARE correlates with the 
known DNA cleaving quinoxaline 1,4-dioxides. Agents of a wide variety of mechanistic actions, 












4.4. CYTOTOXICITY STUDIES OF 1,2-DIALKYNYLIMIDAZOLES AND RELATED N-
ALKYNYLIMIDAZOLES 
As describe above, compound 1a showed cytotoxic against a range of human cancer cells 
and induced apoptosis in the human non-small cell lung cancer cell line A549. In order to 
investigate the effect of 1,2-alkynylimidazole structure on biological activity, the cytotoxicity of 
the 1,2-dialkynyimidazoles 1a-k were determined using the AlamarBlue assay against the A549 
cell line (31) (Table 4.2).  
Within the 1,2-dialkynylimidazole series 1a-g, the cytotoxicity against A549 cells ranges 
from moderate (IC50 ~ 5-6 µM) for 1c,f to high (IC50 = 0.12–0.5 µM) for 1a,d,e.   Both electron-
withdrawing (e.g., 1e) and electron-donating (e.g., 1a) substituents on the phenyl ring within this 
series provide highly cytotoxic analogs; however, this is not uniformly the case (e.g., 1f).   The 
4-substituted analog 1k is marginally more cytotoxic than the 1- and 2-substuted analogs 1i and 
1c; however, 1k is 10-fold less cytotoxic than 1a.  
The aza-Bergman rearrangement of these 1,2-dialkynyliidazoles has been investigated 
theoretically at the B3LYP/6-31G(d,p) level and experimentally by measuring the kinetics of 
rearrangement in 1,4-cyclohexadiene by Dr. Christophe Laroche. There is a good correlation 
between the theoretical and experimental results. However, the cytotoxicity results contrast with 
the DFT calculations and experimental half-lives for Bergman cyclization. The most cytotoxic 
analog in this series, the nitrophenyl substituted compound 1e, has the longest half-life and 
highest predicted Ea for Bergman cyclization. In contrast, the compound predicted to undergo 
Bergman cyclization most readily, 1k, is only moderately cytotoxic. Despite nearly identical 
half-lives from Bergman cyclization, compounds 1a and 1b have IC50 values that differ by a 
factor of five.  
The contrast between the predicted facility with which these 1,2-dialkynylimidazoles 
undergo Bergman cyclization and their cytotoxicity against cancer cells led to a more expansive 
exploration of the structural basis for cytotoxicity of 1b (Table 4.3).   Within a wider structural 
range of 1,2-dialkynylimidazoles 1h-p, there is little variation in cytotoxicity. Hydroxymethyl 
126 
(1j) methoxymethyl (1h) and hydroxyethyl (1n) substitutents on the 2-alkynyl group are all well 
tolerated.  Variation of the 4-phenyl substituent of 1k (e.g., 1m) or benzannulation (e.g., 1o) are 
similarly well tolerated.  In addition, within the 4-substituted and benzannulated series, there is 
little effect in going from a 2-ethynyl substituent (1m,1o) to the 2-p-methoxyphenethynyl 
substitutent (1n,1p). These results led to a more careful examination of the effect of the 1-
alkynyl substituent. Both 2-unsubstituted (5a) and 2-substituted (5b) 1-phenylethynylimidazoles 
are only weakly cytotoxic, as is the 1-methyl-2-alkynylimidazole 7.  However, the 1-
ethynylimidazole 6b displays cytotoxicity on par with that of the 1,2-dialkynylimidazoles 1h-p.  
As these results implicate the 1-ethynyl group in the cytotoxicity of the 1,2-dialkynylimidazole 
1a, selective modification of this group in 1a was explored.  Interestingly, thiophenol selectively 
adds to the 1-ethynyl group of 1a to afford predominantly the (Z)-thioenol ether 8 (Scheme 4.1).  
This modification of the 1-ethynyl group leads to greatly reduced cytotoxicity; the IC50 for 8 is 






















1a 0.5 ± 0.2 17 ± 2 29.7
d 
1b 2.5 ± 0.9 16 ± 1 29.7 
1c 6 ± 3 nd
e
 29.9 
1d 0.5 ± 0.1 nd nd 
1e 0.12 ± 0.02 32 ± 1 30.5 
1f 6 ± 4 nd nd 
1g 2.5 ± 0.9 nd nd 
1i 5.0 ± 0.3 nd 28.9 
1k 2.5 ± 0.9 nd 25.8 
 
Table 4.2. Comparison of Cytotoxicity, Cyclization Rates, and DFT-Predicted Cyclization 
Energy of Activation for a series of 1,2-dialkynylimidazoles. 
a. A549 cells 72 h. 
b. First-order half-life for disappearance of dialkynylimidazole at 110 °C in neat 1,4-
cyclohexadiene. 
c. Predicted energy of activation (Ea = H
‡
 + RT) for the Bergman-type cyclization at 37 °C 
from B3LYP/6-31G(d,p)  DFT calculations. 
d. Experimental Ea at 110 °C is 30.0 kcal/mol, see ref 27. 









Compound IC50 (µM) 
1h 1.0 ± 0.6 
1j 1.9 ± 0.7 
1l 2.0 ± 1.0 
1m 2.6 ± 1.4 
1n 2.5 ± 1.0 
1o 2.0 ± 1.1 
1p 2.9 ± 1.4 
5a 9.2 ± 4.5 
5b       >15 
6b 1.1 ± 0.9 
7 >15 
8 10.1 ± 2.8 
 











4.5. DNA AND PROTEIN CLEAVAGE STUDIES 
In order to address the possible role of DNA or protein cleavage activity as a basis for the 
observed cytotoxicity of 1,2-dialkynylimidazoles, selected compounds were assayed for their 
ability to effect the cleavage of supercoiled plasmid DNA or BSA. Compounds 1a,e,m at 100 
M concentrations were incubated with supercoiled ΦX174 plasmid DNA (50 μM base pair) in 
50 mM Tris buffer, pH 7.0, at 37 °C for 16 h (Figure 4.3). The resulting DNA products were 
separated by agarose gel electrophoresis and visualized by ethidium bromide staining. None of 


















        
Figure 4.3. Supercoiled DNA cleavage assay. Supercoiled ΦX174 plasmid DNA phage DNA (50 
M base pairs) was incubated alone (lane 1), with 100 M 1-propargyl-2-(2-(4-
methoxyphenyl)ethynyl)pyridinium triflate,(32) or with 1,2-dialkynylimidazoles 1m (lane 3), 1e 
(lane 4), or 1a (lane 5) in 50 mM Tris buffer at pH 7 and 13 % (v/v) DMSO for 16 h at 37 °C and 
analyzed by gel electrophoresis (1 % agarose, ethidium bromide stain). Only lane 2 shows 












Compound 1m (500 μM) was incubated with 25 μM BSA in 50 mM Tris buffer, pH 7 at 
either 25 °C or 37 °C for 16 h. No higher-mobility bands corresponding to protein cleavage 








Figure 4.4. Protein cleavage assay. BSA (25 ) was incubated alone (lane 1, at 25 °C, lane 3, 
at 37 °C) in 50 mM Tris buffer at pH 7 or with compound 1m (0.5 mM) (lane 2, at  25 °C, lane 
4, at 37 °C ) for 16 h at 25 °C or 37 °C and analyzed by 10 % SDS-PAGE. No protein cleavage 







In summary, despite the ability of these 1,2-dialkynylimidazoles to undergo Bergman 
rearrangement to diradical/carbene intermediates under relatively mild conditions, there is no 
correlation between the rate of Bergman cyclization and cytotoxicity to A459 cells.  Even 1,2-
diethynylimidazoles such as 1k that are predicted to undergo cyclization at physiological 
temperatures are not as cytotoxic as 1,2-dialkynylimidazoles such as 1a that do not undergo any 
appreciable cyclization at this temperature. The p-nitrophenyl aubstituted 1,2-dialkynylimidazole 
1e, which undergoes cyclization at about one-half the rate of 1a is four-fold more cytotoxic than 
1a.   
There is no evidence that the cytotoxicity of these 1,2-dialkynylimidazoles is due to DNA 
cleavage or non-specific protein cleavage. Unlike other cytotoxic aza-enediynes that cleave 
supercoiled DNA at micromolar concentration via a hydrogen atom abstraction from the 
deoxyribose backbone, dialkynylimidazole 1a,e,m do not cleave supercoiled DNA, even at 100 
M concentrations. Certain enediynes analogs have been shown to cleave a variety of proteins, 
and hydrogen abstraction from proteins is a mechanism for self-resistance to naturally occurring 
enediynes. However, there is no effect of 1,2-dialkynylimidazole 1m on BSA, even at 
concentrations over 100-times higher than the IC50 for this compound.  
These observations rule out a role for an unfacilitated Bergman cyclization in the 
cytotoxicity of these 1,2-dialkynylimidazoles. However, it is likely that 1,2-dialkynylimidazole 
with Bergman cyclization barriers even lower than 1k can be designed by encompassing the 
dialkynes in 9- or 10-membered rings, and these may function as cytotoxic agents via 
spontaneous Bergman cyclization. Alternatively, 1,2-dialkynylimidazoles could be designed to 
undergo cyclization more rapidly when bound to DNA or proteins, leading to the production of 
diradical or carbene intermediates capable of modifying these binding partners.  It is possible 
that this sort of facilitated cyclization gives rise to the enhanced cytotoxicity of certain 1,2-
dialkynylimdiazoles examine here such as 1a,d, and e. Finally, just as certain acyclic enediynes 
have been shown to display potent anticancer effects independent of their Bergman cyclization 
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potential, the enhanced cytotoxicity of the 1,2-dialkynylimidazoles examined here may not 
involve aza-Bergman cyclization at all.  
An alternative or additional mechanism for the cytotoxicity of these 1,2-
dialkynylimidazoles has been revealed from the study of structurally related alkynylimidazoles 
presented here. Although not as cytotoxic as the 1,2-dialkynylimidazoles 1a,d, and e, the N-
ethynylimidazole 6b is at least as cytotoxic as the other 1,2-dialkynylimidazoles examined.  
Interestingly, the N-ethynyl group of the 1,2-dialkynylimidazole 1a was found to react 
selectively with thiophenol, and this addition abrogates the cytotoxicity of this compound.  This 
unexpected electrophilic nature of the imidazole N-ethynyl group bears further study, as it stands 
in contrast with the established role of related N-alkynyl heterocycles and N-alkynylamides as 
electron-rich, nucleophilic species. In light of this reactivity and the lack of DNA cleavage 
ability, the 1,2-dialkynylimidazoles and 1-alkynylimidazoles may have more in common with 
other heterocyclic, thiol-reactive anticancer agents than the enediyne natural products or recently 
reported DNA-cleaving cytotoxic lysine-acetylene conjugates. Interestingly, certain 1,2-
dialkynylimidazoles such as 1a and 1e are notably more cytotoxic against A549 cells than thiol-
reactive heterocycles currently in clinical trials. Thus, the potential of N-ethynylimidazoles to 
react with biological thiols deserves further investigation, and studies exploring this possibility 







4.7. EXPERIMENTAL SECTION 
General: All reactions were carried out under argon in oven-dried glassware with magnetic 
stirring. Unless otherwise noted, all materials were obtained from commercial suppliers and were 
used without further purification. THF was distilled from sodium/benzophenone prior to use. 
Flash chromatography was performed with EM Reagent silica gel (230–400 mesh) using the 




C NMR spectra were determined in CDCl3 on a spectrometer operating at 400 and 100 
MHz, respectively, and are reported in ppm using solvent as internal standard (7.26 ppm for 
1
H 
and 77.0 ppm for 
13
C in CDCl3). Mass spectra were obtained in the positive mode either by 
chemical ionization using methane as the ionizing gas or by electrospray ionization. The purity 















Typical procedure for the synthesis of 1,2-dialkynylimidazoles:  
1-ethynyl-2-(2-(4-methoxyphenyl)-ethynyl)-1H-benzimidazole (1p): To a solution of 2-iodo-1-
(2-triisopropylsilylethynyl)-1H-benzimidazole 4g (212 mg, 0.5 mmol) in Et3N (10 mL) under 
argon was added 4-ethynylanisole (0.075 mL, 0.55 mmol), Pd(PPh3)4 (30 mg, 0.026 mmol) and 
CuI (10 mg, 0.05 mmol). The reaction mixture was stirred at 50 °C until complete consumption 
of 4 g. The solvent was removed under reduce pressure and the residue was purified by flash 
chromatography (0-5 % EtOAc/hexane) to afford 210 mg (98 %) of the TIPS-protected 
compound as a yellow crystalline solid. To this material in THF (10 mL) at -78 °C was added 
TBAF (0.5 mL of 1 M solution in THF, 0.5 mmol) and the mixture was stirred at -78 °C until 
completion. The reaction mixture was quenched at -78 °C with 10 mL of water and extracted 
with CH2Cl2 (3×25 mL). The organic layers were combined, dried over Na2SO4 and the solvent 
was evaporated under reduced pressure. The residue was purified by flash chromatography (0-20 
% EtOAc/hexane) to afford 122 mg (92 %) of compound 1p as a white solid: mp 140.1-141.3 
°C; 
1
HNMR(400MHz, CDCl3) δ 7.75 (d, J = 7.4 Hz, 1H), 7.58 (d, J = 7.4 Hz, 1H), 7.50 (d, J = 
8.8 Hz, 2H), 7.37 (p, J = 7.6 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 3.81 (s, 3H), 3.46 (s, 1H). 
13
C 
NMR (100 MHz, CDCl3) δ 160.9, 141.7, 138.8, 134.6, 134.0, 125.2, 124.6, 120.4, 114.2, 112.5, 
110.7, 96.6, 79.9, 69.7, 64.4, 55.3. MS m/z: HRMS calc for C18H13N2O (M
+
) 273.1028, found 


















Following the general procedure described above (flash chromatography; 0-20 % 
EtOAc/hexane), we obtained 7.8 mg of 1m (82 % overall yield) as an off-white solid: mp 89.7-
91.5 C; 
1
H NMR (400 MHz, CDCl3) δ 7.75-7.72 (2H, m), 7.34 (1H, s), 7.10-7.06 (2H, m), 3.44 
(1H, s), 3.24 (1H, s). 
13
C NMR (100 MHz, CDCl3) δ 162.6 (d, J = 246 Hz), 141.2, 134.4, 128.1 
(d, J = 2.9 Hz), 127.1 (2C, d, J = 8.2 Hz), 117.2, 115.7 (2C, d, J = 21.6 Hz), 82.7, 71.5, 70.4, 
62.3; MS m/z: HRMS (CI) calc for C13H8N2F (M
+

































To a solution of 1a (20 mg, 0.09 mmol) in THF (2 mL) was added thiophenol (0.1 mmol, 0.01 
mL). The reaction mixture was stirred at room temperature for 5 days. The reaction mixture was 
concentrated, and the residue was purified by flash chromatography (30% EtOAc/hexane) to 
afford 8 as a brown thick oil (13 mg, 43% yield). 1HNMR(400 MHz, CDCl3) δ 7.71 (1H, s), 
7.53-7.50 (2H, m), 7.47-7.44 (2H, m), 7.39-7.35 (2H, m), 7.33-7.29 (1H, m), 7.20 (1H, d, J = 8.4 
Hz), 6.91-6.88 (2H, m), 6.17 (2H, d, J = 8.4 Hz), 3.83 (3H, s).
13
C NMR (100 MHz, CDCl3) δ 
160.4, 134.3, 133.4 (2C), 132.6, 130.1 (2C), 129.4 (2C), 127.7, 121.1, 119.1, 115.5, 114.1 (2C), 
113.5, 99.2, 77.2, 55.3; MS m/z: HRMS (CI) calc for C20H17N2OS (M
+
) 333.1062; found, 
333.1063.  
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FACS analysis:  
A549 Cells (2.0 x 10
5
 cells) were plated in a 12-well plate in a final volume of 1 ml/well of F-
12K with L-glutamine medium. After 24 h incubation at 37 °C in an atmosphere of 5 % CO2, 
cells were treated with 1 μl of compound 1a (5 μM, 2.5 μM, 1.25 μM and 0.625 μM). After 24 h, 
cells were rinsed with PBS and trypsinized. The cells were pelleted at 400 x g for 4 min, washed 
with annexin binding buffer (ABB), and pelleted again at 400 x g for 4 min. The media was 
aspirated and the cells were resuspended in ABB and stained with annexin V-FITC (5 μg/mL) 
for 8 min at room temperature. Propidium iodide (2 μg/mL) was added to the cell suspension. 
















Supercoiled plasmid DNA cleavage assay:  
The DNA cleavage efficiency was determined by incubation of 3 with solutions of supercoiled 
ΦX174 plasmid DNA (50 μM base pairs) in 50 mM N,N,N-tris(hydroxymethyl)aminomethane 
(Tris) buffer at pH 7. The reaction mixtures containing 100 µM test compound, 100 µM 1-
propargyl-2-(2-(4-methoxyphenyl)ethynyl)pyridinium triflate1 as positive control, or vehicle 
(13% (v/v) DMSO) were incubated for 16 h at 37 °C.  DNA products were separated by agarose 
gel electrophoresis [1 × Tris-borate-N,N,N’,N’-ethylenediaminetetraacetic acid (EDTA) (TBE) 
at 90 V for 1 h], stained with ethidium bromide (0.25 μg/mL), and the images were analyzed 
using a fluorimager with ImageQuant software. The degree of cleavage of Form I DNA was 
determined using equation 2. 
Percent cleavage  =           (eq 1) 
The reported, normalized percent cleavage accounts for cleavage in control samples 
under the reaction conditions employed and this was calculated according to equation 3. 
Where Form II refers to relaxed, circular DNA, Form III is linear, duplex DNA. The 
reported, normalized percent cleavage accounts for cleavage in control samples under the 
reaction conditions employed and this was calculated according to equation 3. 







(2X[Form III]+[Form II] +[Form I]
X100
% cleavage (drug)-% cleavage (control)
100-% cleavage control
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Protein Cleavage Assay:  
Bovine serum albumin (25 μM, Fisher Bioreagent) was incubated alone or with 0.5 mM of 1,2-
dialkynylimidazole 1m in 50 mM Tris buffer at pH 7 at 25 °C or 37 °C for 16 h. The protein 
samples were analyzed by 10 % SDS-PAGE and stained with Coomassie Blue. 
Alamar Blue Assay: 
Cell viability was determined using the AlamarBlue reagent (AbD Serotec). This reagent can be 
used to easily detect changes in cell proliferation based on the ability of viable cells to cause 
AlamarBlue to change from its oxidized (non-fluorescent) to a reduced(fluorescent) form. Cell 
culture cytotoxicity assays were carried out as described by Kumar et al.(31) Aliquots of 100 μl 
cell suspension (1-3x10
3
 cells) were placed in microtiter plates in an atmosphere of 5% CO2 at 
37 °C. After 24 h, 100 μL of culture media and 2 μl of the compound in DMSO were added to 
each well in duplicate, and the plates incubated an additional 24 or 72 h at 37 °C. There was no 
effect on the growth of cells compared to that of cells in culture media alone at this DMSO 
concentration. Compounds, along with Mitomycin-C (MP Biomedicals) as a positive control 
were evaluated at final concentrations ranging from 0.001 to 50 μM. After 72 h incubation, the 
culture media was removed from each well, and 200 μL of fresh media and 20 μL of AlamarBlue 
reagent were added, followed by additional 6 h incubation. Cell viability was detected by 
fluorescence intensity using a Beckman Coulter DTX880 plate reader with excitation at 530 nm 
and emission at 590 nm. The fluorescence data obtained from the cytotoxicity studies was used 
to calculate the percent growth according to the following equation: 
% Growth = 100*(MeanFtest – Mean Ftime0)/ (MeanFctrl – Mean Ftime0) (eq 3) 
Where: 
Mean Ftime0 = the averaged measured fluorescence intensities of AlamarBlue reagent at 
the time just before the exposure of the cells to the test substance. 
Mean Ftest = the averaged measured fluorescence intensities of AlamarBlue reagent after 
72 h exposure of the cells to the test substance at a particular concentration. 
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Mean Fcrtl = the averaged measured fluorescence intensities of AlamarBlue reagent after 
72 h exposure of the cells to the vehicle without the test substance. 
The IC50 (50 % Inhibition Concentration) is defined as the test compound concentration 
where the increase from time0 in the number of mass of treated cells was only 50 % as much as 
the corresponding increase in the vehicle-control at the end of the experiment. The IC50 values of 
1,2-dialkynylimidazole and related N-alkynylimidazole analogs were determined by non-linear 
regression using the program Grafit and fitting the data to the following equation:  
y = Min + (Max-Min)/(1+10^((x-logIC50)*Hill slope)) (eq 4) 
Where: 
Min= the minimum response plateau (0 % Growth) 
Max= the maximum response plateau (100 % Growth) 
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                           X-ray Crystallography Data for Compound 7b 

























X-ray Experimental for Compound 7b:  Crystals grew as colorless plates by slow 
evaporation from CH2Cl2, MeOH and hexane.  The data crystal was cut from a larger crystal and 
had approximate dimensions; 0.50 x 0.11 x 0.10 mm.  The data were collected on a Nonius 
Kappa CCD diffractometer using a graphite monochromator with MoK radiation ( = 
0.71073Å).  A total of 211 frames of data were collected using -scans with a scan range of 2 
and a counting time of 228 seconds per frame.  The data were collected at 153 K using an Oxford 
Cryostream low temperature device.  Details of crystal data, data collection and structure 
refinement are listed in Table 1.  Data reduction were performed using DENZO-SMN.
1
  The 
structure was solved by direct methods using SIR97
2
 and refined by full-matrix least-squares on 
F2 with anisotropic displacement parameters for the non-H atoms using SHELXL-97.
3
  The 
hydrogen atoms were observed in a F map and refined with isotropic displacement parameters.  
The function, w(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[((Fo))2 + (0.041*P)2 + 
(0.319*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.105, with R(F) equal to 0.0415 and a 
goodness of fit, S, = 1.02.  Definitions used for calculating R(F), Rw(F2) and the goodness of fit, 
S, are given below.
4
  The data were corrected for secondary extinction effects.  The correction 
takes the form:  Fcorr = kFc/[1 + (1.5(4)x10-5)* Fc2 3/(sin2)]0.25 where k is the overall scale 
factor.  Neutral atom scattering factors and values used to calculate the linear absorption 
coefficient are from the International Tables for X-ray Crystallography (1992).
5  All figures were 
generated using SHELXTL/PC.
7
  Tables of positional and thermal parameters, bond lengths and 
angles, torsion angles, figures and lists of observed and calculated structure factors are located in 
tables 1 through 7.   Crystallographic data (excluding structure factors) for compound 7b have 








Table 1.  Crystal data and structure refinement for 7b. 
Empirical formula  C25 H16 F N3 O 
Formula weight  393.41 
Temperature  153(2) K 
Wavelength  0.71070 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.1511(4) Å = 94.044(1)°. 
 b = 11.0903(6) Å = 103.875(1)°. 
 c = 13.0643(8) Å  = 104.478(1)°. 
Volume 964.50(10) Å3 
Z 2 
Density (calculated) 1.355 Mg/m3 
Absorption coefficient 0.091 mm-1 
F(000) 408 
Crystal size 0.50 x 0.11 x 0.10 mm 
Theta range for data collection 1.91 to 27.45°. 
Index ranges -7<=h<=9, -14<=k<=13, -16<=l<=16 
Reflections collected 6831 
Independent reflections 4362 [R(int) = 0.0160] 
Completeness to theta = 27.45° 99.0 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4362 / 0 / 336 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0415, wR2 = 0.0953 
R indices (all data) R1 = 0.0574, wR2 = 0.1046 
Extinction coefficient 1.5(4)x10
-5 
Largest diff. peak and hole 0.186 and -0.171 e.Å-3 
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 Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 7b.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
F1 3039(2) 10852(1) 3211(1) 61(1) 
N2 2570(2) 6032(1) 5761(1) 24(1) 
N3 2448(2) 4195(1) 4892(1) 24(1) 
N4 2135(2) 3923(1) 953(1) 34(1) 
O5 1188(2) 2852(1) 8863(1) 35(1) 
C6 2528(2) 4780(1) 5819(1) 24(1) 
C7 2553(2) 6241(1) 4722(1) 23(1) 
C8 2445(2) 5089(1) 4200(1) 23(1) 
C9 2624(2) 4261(1) 6789(1) 27(1) 
C10 2770(2) 3832(1) 7605(1) 29(1) 
C11 3015(2) 3278(2) 8600(1) 41(1) 
C12 2729(2) 7496(1) 4386(1) 25(1) 
C13 1357(2) 8164(1) 4494(1) 29(1) 
C14 1474(2) 9306(1) 4103(1) 37(1) 
C15 2961(3) 9754(1) 3619(1) 39(1) 
C16 4370(3) 9138(1) 3524(1) 39(1) 
C17 4254(2) 8002(1) 3917(1) 32(1) 
C18 2315(2) 4712(1) 3078(1) 23(1) 
C19 1818(2) 5433(1) 2274(1) 27(1) 
C20 1767(2) 5008(1) 1245(1) 31(1) 
C21 2563(2) 3224(1) 1726(1) 32(1) 
C22 2672(2) 3577(1) 2780(1) 27(1) 
C23 2600(2) 6858(1) 6595(1) 26(1) 
C24 2578(2) 7465(1) 7377(1) 28(1) 
C25 2537(2) 8158(1) 8339(1) 27(1) 
C26 2990(2) 7682(1) 9301(1) 32(1) 
C27 2900(2) 8324(2) 10231(1) 38(1) 
C28 2390(2) 9444(2) 10212(1) 41(1) 
C29 1946(2) 9927(1) 9267(1) 41(1) 
C30 2002(2) 9286(1) 8328(1) 34(1) 
________________________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  7b. 
 
 
F1-C15  1.3577(16) 
N2-C23  1.3656(16) 
N2-C6  1.3886(16) 
N2-C7  1.3901(16) 
N3-C6  1.3153(16) 
N3-C8  1.3878(16) 
N4-C21  1.3394(19) 
N4-C20  1.3431(19) 
O5-C11  1.4068(19) 
O5-H5  0.92(2) 
C6-C9  1.4218(18) 
C7-C8  1.3806(17) 
C7-C12  1.4729(18) 
C8-C18  1.4703(17) 
C9-C10  1.1903(18) 
C10-C11  1.4682(19) 
C11-H11A  0.99(2) 
C11-H11B  1.04(2) 
C12-C17  1.3939(19) 
C12-C13  1.3954(19) 
C13-C14  1.389(2) 
C13-H13  0.969(16) 
C14-C15  1.371(2) 
C14-H14  0.978(18) 
C15-C16  1.374(2) 
C16-C17  1.384(2) 
C16-H16  0.965(19) 
C17-H17  0.988(17) 
C18-C22  1.3928(18) 
C18-C19  1.3960(18) 
C19-C20  1.3827(19) 
C19-H19  0.968(16) 
C20-H20  1.007(16) 
C21-C22  1.3835(19) 
C21-H21  0.997(17) 
C22-H22  0.979(15) 
C23-C24  1.1898(18) 
C24-C25  1.4357(18) 
C25-C26  1.395(2) 
C25-C30  1.396(2) 
C26-C27  1.388(2) 
C26-H26  1.007(16) 
C27-C28  1.380(2) 
C27-H27  1.012(19) 
C28-C29  1.380(2) 
C28-H28  0.978(18) 
C29-C30  1.389(2) 
C29-H29  0.953(19) 

















































































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for 7b.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
F1 85(1)  34(1) 73(1)  28(1) 27(1)  19(1) 
N2 26(1)  27(1) 19(1)  4(1) 7(1)  7(1) 
N3 25(1)  28(1) 22(1)  6(1) 7(1)  8(1) 
N4 36(1)  38(1) 25(1)  0(1) 11(1)  7(1) 
O5 43(1)  41(1) 24(1)  8(1) 14(1)  11(1) 
C6 23(1)  26(1) 24(1)  6(1) 6(1)  6(1) 
C7 22(1)  29(1) 20(1)  5(1) 6(1)  7(1) 
C8 21(1)  26(1) 22(1)  6(1) 6(1)  7(1) 
C9 27(1)  30(1) 24(1)  5(1) 8(1)  7(1) 
C10 30(1)  35(1) 26(1)  6(1) 10(1)  10(1) 
C11 40(1)  61(1) 30(1)  21(1) 14(1)  21(1) 
C12 29(1)  23(1) 20(1)  2(1) 5(1)  6(1) 
C13 33(1)  29(1) 26(1)  2(1) 8(1)  8(1) 
C14 46(1)  30(1) 37(1)  5(1) 9(1)  16(1) 
C15 54(1)  23(1) 38(1)  11(1) 10(1)  8(1) 
C16 45(1)  33(1) 38(1)  11(1) 18(1)  4(1) 
C17 34(1)  30(1) 33(1)  6(1) 12(1)  8(1) 
C18 20(1)  26(1) 22(1)  3(1) 6(1)  4(1) 
C19 28(1)  29(1) 25(1)  5(1) 6(1)  9(1) 
C20 33(1)  36(1) 23(1)  6(1) 6(1)  7(1) 
C21 34(1)  31(1) 31(1)  -1(1) 11(1)  8(1) 
C22 28(1)  26(1) 27(1)  5(1) 8(1)  7(1) 
C23 27(1)  29(1) 23(1)  5(1) 7(1)  8(1) 
C24 28(1)  30(1) 26(1)  5(1) 7(1)  7(1) 
C25 24(1)  30(1) 26(1)  0(1) 7(1)  5(1) 
C26 35(1)  35(1) 28(1)  3(1) 8(1)  13(1) 
C27 38(1)  49(1) 27(1)  1(1) 9(1)  11(1) 
C28 39(1)  41(1) 39(1)  -9(1) 17(1)  6(1) 
C29 41(1)  29(1) 57(1)  1(1) 24(1)  10(1) 
C30 35(1)  34(1) 38(1)  9(1) 15(1)  12(1) 
______________________________________________________________________________  
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 7b. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H22 2970(20) 3014(14) 3303(12) 28(4) 
H13 290(20) 7823(14) 4815(12) 33(4) 
H30 1650(20) 9589(15) 7650(13) 40(4) 
H17 5250(20) 7544(15) 3861(13) 39(4) 
H26 3340(20) 6859(15) 9316(12) 36(4) 
H19 1450(20) 6205(15) 2395(12) 34(4) 
H14 510(30) 9783(17) 4152(14) 49(5) 
H20 1400(20) 5527(14) 667(12) 35(4) 
H21 2810(20) 2408(16) 1515(13) 40(4) 
H11A 4010(30) 3915(18) 9173(16) 60(6) 
H16 5370(30) 9493(17) 3168(15) 56(5) 
H28 2360(30) 9888(17) 10879(14) 50(5) 
H11B 3610(30) 2532(19) 8503(16) 64(6) 
H29 1570(30) 10694(18) 9236(14) 53(5) 
H5 1430(30) 3196(19) 9558(17) 66(6) 
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